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ABSTRACT 
Post-translational modification of amino acid side chains of proteins is an important 
mechanism that allows cells to regulate the function of the modified protein. Mono-ADP-
ribosylation is an example of an important covalent, post-translational protein modification. 
Mono-ADP-ribosylation is the covalent attachment of the ADP-ribose group from NAD+ to 
an acceptor amino acid residue, oftentimes arginine. A variety of bacterial enzymes catalyze 
this reaction to bring about disease symptoms in eukaryotes or even regulate nitrogen 
fixation in response to differing environmental conditions. The eukaryotic family of 
enzymes that catalyze this reaction are called mono-ADP-ribosyltransferases (ARTs). The 
enzymes responsible for the removal of the ADP-ribose group from the modified amino acid 
residue are named ADP-ribosylglycohydrolases. Together the ARTs and the hydrolases 
constitute opposite arms of an ADP-ribosylation cycle that can regulate protein function. 
Both enzymes are expressed together in several mammalian tissues, particularly skeletal 
muscle. 
Skeletal muscle myogenesis and terminal differentiation are highly regulated 
pathways that involve regulation by important growth and transcription factors and specific 
changes in gene expression. Previous studies have shown that specific inhibitors of ARTs 
can reversibly block terminal myogenic differentiation, and that ART activity is increased 
upon terminal differentiation. ART activity has been shown in adult skeletal muscle, but it is 
not known which of the five currently known ART enzymes are responsible for this activity. 
Four of these known ARTs appear to be glycosylphosphatidylinositol-anchored, extracellular 
membrane proteins, but cytoplasmic ART activity has been identified in muscle and other 
tissues. Furthermore, the embryonic expression of these ARTs and ADPRH has not been 
established. Thus, the role of specific ART enzymes in regulation of myogenesis remains to 
be characterized. 
The objectives of the work described in this thesis were to: (1) establish the pattern of 
expression of the muscle specific Arts and Adprh during embryonic differentiation, using the 
mouse as an experimental model, and (2) determine the quantitative pattern of expression of 
the Arts and Adprh relative to specific muscle regulatory genes in differentiating mouse 
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myoblast cell cultures and the effect of inhibiting ART activity on these expression patterns. 
In situ hybridization was used to examine the expression pattern of Arts in mouse embryos, 
and quantitative RT-PCR was used to characterize gene expression in mouse myogenic cell 
cultures. 
Results of in situ hybridization with probes for the three muscle-expressed Art genes 
(1, 3, and 5) showed that expression of Arts is restricted to the dorsal-medial lip of the 
dermamyotome in mouse embryos at embryonic day 10.5. This expression decreases and is 
less restricted at later stages of development. Expression of Art 1, Arta and Adprh is seen 
throughout the embryo and does not change with time. This is the first known study to 
describe the pattern of embryonic expression of these key genes involved in ADP-
ribosylation in muscle. Results of quantitative RT-PCR on differentiation of mouse C2C 12 
myoblast cultures demonstrated a significant increase in expression of both Arts 1 and 5 after 
4 days in differentiation media, which correlated with the morphological changes associated 
with terminal differentiation of the myoblasts to form multinucleated myotubes. Expression 
of Adprh, as well as key genes involved in myogenesis (Myodl, myogenin, and P21) 
demonstrated a transient increase at day 3, before terminal differentiation and the increased 
expression of Arts 1 and 5. Inhibition of ART enzyme activity with meta-
iodobenzylguanidine blocked terminal differentiation and inhibited the increases in 
expression seen in control cultures for all of the genes examined. 
The expression of the Arts and Adprh in early embryo development of the mouse and 
during terminal differentiation of C2C 12 cell cultures suggests that these enzymes play an 
important role in the regulation of these processes. Blocking activity of the ART enzymes 
causes a dramatic change in gene expression of key genes involved in myogenesis. The 
mechanisms that the ADP-ribosylation enzymes employ to cause these effects are currently 
not known. The research presented herein provides insight into when these genes are 
expressed in the mouse embryo and the effect of blocking activity of the ART enzymes on 
terminal differentiation of mouse skeletal muscle myoblasts in culture. 
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CHAPTER 1. GENERAL INTRODUCTION 
Introduction 
The primary goal of the research presented in this thesis was to examine the function 
of the ADP-ribosylation enzymes in skeletal muscle differentiation and growth. ADP-
ribosylation is a reversible post-translational modification, and the removal of the ADP-
ribose group is carried out by ADP-ribosylglycohydrolases. Several lines of evidence show 
that ADP-ribosylation is a crucial regulator of muscle cell differentiation in vitro, but it is 
currently not known which of the mono-ADP-ribosyltransferases (ARTs) is responsible for 
this regulation of differentiation. ART activity has been demonstrated in adult skeletal 
muscle of many mammalian and avian species, yet it is currently not known which of the 
ARTs is responsible for this activity, and it is unknown as to which members of the ART 
family are expressed in the developing somites in the early stages of myogenesis. The 
studies described in this thesis were aimed at determining expression of the ADP-ribosylation 
enzymes in the developing mouse embryo and in the C2C12 mouse skeletal myoblast cell 
line. These two models allow us to examine expression of these key enzymes at different 
stages in the myogenic pathway. An inhibitor of ART activity was also used in the C2C 12 
gene expression studies to examine how the cell cultures changed gene expression in 
response to blocking ART enzyme activity. The results provide insight into the expression of 
the enzymes involved in the ADP-ribosylation cycle at different stages in muscle 
development. 
This thesis describes in detail the studies carried out to determine localization of gene 
expression in mouse embryos and quantitation of gene expression in C2C 12 cell cultures. 
The results show, for the first time, that the ADP-ribosylation enzymes show specific 
patterns of expression during embryonic development. The studies examining C2C 12 gene 
expression levels show that gene expression of the ADP-ribosylation enzymes is affected by 
the normal terminal differentiation of these cells and by treatment of the cells with a specific 
inhibitor of ART enzyme activity. These studies help to extend our knowledge of the 
biological role of ADP-ribosylation in muscle. 
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Thesis Organization 
This thesis is organized in the manuscript-based format with the inclusion of one 
paper. The manuscript presented in this thesis will be submitted to the peer-reviewed journal 
Cell and Tissue Research for publication. I was responsible for planning and carrying out 
almost all of the experiments described within this thesis. In situ hybridization assays were 
performed with expertise provided by Mary Sue Mayes, an assistant scientist in the group. 
Embryo collection was done with the help of Dr. Christian Paxton. 
Literature Review 
Many different types of post-translational modifications have been shown to be 
involved in many important cellular processes, including cellular signaling, protein 
localization, and enzyme activity (Walsh et al., 2005). ADP-ribosylation is the post-
translational protein modification in which the ADP-ribose moiety from NAD+ is transferred 
to a specific amino acid residue. There are two general types of ADP-ribosylation, poly-
ADP-ribosylation and mono-ADP-ribosylation. Poly-ADP-polymerase action results in the 
addition of chains of ADP-ribose attached to an acceptor protein. Poly-ADP-ribosylation is 
carried about by a family of poly-ADP-ribose polymerase (PARP) enzymes that are involved 
in DNA repair and the maintenance of telomeric DNA in eukaryotes (Shall, 2002). Mono-
ADP-ribosylation is similar to phosphorylation in that both of these modifications are 
reversible and found to regulate the function of the modified protein. A list of the currently 
known eukaryotic mono-ADP-ribosyltransferase enzymes and their substrates are listed in 
Table 1 (modified from Corda & Di Girolamo, 2003). Hydrolases that catalyze the removal 
of the ADP-ribose group to regenerate unmodified protein have also been identified in many 
vertebrate tissues. Thus, this ADP-ribosylation cycle (Figure 1, from Okazaki &Moss, 
1999) may play an integral role in protein function (Okazaki &Moss, 1999). A complete, 
functional ADP-ribosylation cycle was first confirmed in the nitrogen fixing bacterium 
Rhodospirillum rubrum (Ludden 1994). A key enzyme in nitrogen fixation, dinitrogen 
reductase, is regulated by mono-ADP-ribosylation and the reversal of this ADP-ribosylation 
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is carried out by the enzyme dinitrogen reductase ADP-ribosylarginine glycohydrolase 
(Ludden 1994). Homologs of the ADP-ribosylarginine hydrolase enzyme have been found in 
many phylogenetic classes including eukaryota, bacteria, and viruses. 
Mono-ADP-ribosyltransferases have been detected in viruses, bacteria and eukaryotic 
cells. The bacterial toxin transferases are the most well-known and classified ADP-
ribosyltransferases to date. Diphtheria toxin was the first bacterial toxin to be identified as a 
mono-ADP-ribosyltransferase (Honjo et al., 1971) and has since been shown to modify a 
diphthamide (a modified histidine residue) in elongation factor 2, which inactivates protein 
synthesis in human mucous membranes and epithelial cells (Koch-Nolte &Haag, 1997). 
Pseudoinonas aeruginosa exotoxin A can also modify this same dipthamide residue in 
elongation factor 2 (Iglewski et al., 1977). Cholera toxin and Escherichia coli enterotoxin 
(LT) both ADP-ribosylate arginine 187 in the Gsa subunit of the heterotrimeric guanine 
nucleotide-binding protein causing an increase in cANIP levels (Moss &Vaughan, 1988). 
Many members of the family of Clostridium toxins (C2, iota, spiroforme, and CDT) can 
ADP-ribosylate nonmuscle actin (Aktories, 1994). ADP-ribosylation of nonmuscle actin by 
the iota and C2 toxins prevent actin polymerization in vitro and in F9 cells, platelets, CHO 
cells and Xenopus oocytes (Aktories, 1994; Okazaki &Moss, 1999). The C3 family of 
Clostridium toxins ADP-ribosylate an asparagine in the small GTP-binding proteins of the 
Rho family, disrupting the actin cytoskeleton (Aktories 1994). Due to the substrate 
specificity of many of these bacterial toxins they have been proven useful as tools to analyze 
the specific details of G protein mediation of hormonal effects at a molecular level (Ohishi 
2000). The identification and characterization of the bacterial toxins has shaped our current 
understanding of the biology of ADP-ribosylation and has been useful in characterizing the 
endogenous transferases found in animal tissues. 
The bacterial toxins and mammalian mono-ADP-ribosyltransferases (ARTs) are only 
able to ADP-ribosylate specific amino acid residues found in proteins. The ADP-
ribosylation of arginine, asparagine, cysteine, lysine and diphthamide residues has been 
identified in eukaryotes (Ueda & Hayaishi, 1985). The non-enzymatic ADP-ribosylation of 
lysine and cysteine has also been reported; however, the remaining modifications appear to 
be due to specific ARTs (Jacobson et al., 1994; Itoga et al., 1997). The vertebrate ARTs are 
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expressed in lymphatic tissues, testis, bone marrow, erythroblasts and cardiac and skeletal 
muscle. Mono-ADP-ribosyltransferases have been cloned from rabbit and human skeletal 
muscle, chicken polymorphonuclear granulocytes and nucleoblasts, and mouse lymphoma 
cell lines Yac-1 and SL12 (Weng et al., 1999). The majority of the cloned transferases are 
arginine-specific transferases, and this specific modification is the one that will be described 
in the remainder of this introduction. 
Currently there are five known members of the mammalian arginine-specific mono-
ADP-ribosyltransferase family, designated ART 1-5. All contain an N-terminal signal 
sequence that suggests they are secreted enzymes. ART 5 is the only enzyme that does not 
contain the second, C-terminal hydrophobic region that is characteristic of GPI-anchored 
membrane proteins (Glowacki et al., 2002). 
An ART from rabbit skeletal muscle microsomes, later identified as ART1, was first 
purified and partially characterized by Dr. Donald Graves' group (Peterson et al., 1990) at 
Iowa State University. ART1 was also purified from rabbit skeletal muscle as a 36-kDa 
protein (Zolkiewska et al., 1992) and has been cloned from rabbit (Zolkiewska et al., 1992) 
and human skeletal muscle and mouse lymphoma cells (Okazaki et al., 1997). The amino-
and carboxyl-terminal signal peptides found in the sequence of ARTl are characteristic of a 
GPI-anchor signal. Artl expression is restricted to cardiac and skeletal muscle, spleen, lung, 
liver, and embryonic tissues (Braren et al., 1998; Glowacki et al., 2002). ART activity is 
released from the membrane of rat mammary adenocarcinoma (I~fMU) cells transformed with 
the cDNA of Artl upon treatment with phosphatidylinositol-specific phospholipase C (PI-
PLC) (Zolkiewska et al., 1992) confirming that ART1 activity is membrane associated and 
very likely to be GPI-anchored to the membrane. ART 1 is thought to be the GPI-anchored 
enzyme that is responsible for the modification of integrin a7 in C2C 12 mouse myoblasts 
(Zolkiewska &Moss, 1995). Another member of the integrin family, LFA-1, is modified by 
a stably transfected GPI-anchored ART1 in mouse cytotoxic T lymphocytes (Nemoto et al., 
1996; Liu et al., 1999). Moss' group, using truncated mutants of ART1, identified regions of 
ART1 that influenced transferase and NAD glycohydrolase activity (Bourgeois et al., 2003). 
The regions found in the amino- and carboxyl-terminal of ARTl are also found in other 
ARTs suggesting conservation of structure and function across the ART family. Recent 
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studies examining the ADP-ribosylation of human neutrophil peptide-1 (HNP-1) have shown 
that human ART1 is the primary ART involved in modifying HNP-1 and that this 
modification only occurs in inflammatory and disease conditions found in patients with 
chronic lung disorders (Panne et al., 2006). 
ART2 is the T-cell antigen known as RT6 in rodents. In rats RT6a and RT6b are 
alleles of a single gene that encodes the T-cell antigens RT6.1 and RT6.2 respectively. 
RT6.1 is Art2.1 and RT6.2 is Art2.2 (Haag et al., 1990). The crystal structure of rat ART2.2 
(RT6.2) was recently reported and the authors suggest that the conservation of the "four-
stranded (3-core" indicates that all eukaryotic ARTs have a common ancestor (Mueller-
Dieckmann et al., 2002). Recombinant mouse ART2.1 and ART2.2 have been shown to 
ADP-ribosylate histones and a variety of synthetic substances in vitro (Rigby et al., 1996). 
Recent investigations of mouse ART2.2 have shown that exposure of T-cells to endogenous 
micromolar levels of NAD+ have led to NAD-induced cell death (NICD) (Seman et al., 
2003). It was shown that NICD-required the ART2 catalyzed ADP-ribosylation of P2X7, a 
member of the purinoceptor family of cell surface proteins. Upon activation of P2X7 by 
ADP-ribosylation cells underwent phosphatidylserine flashing (an early marker of apoptosis), 
changes in cytosolic calcium, and non-selective pore formation in the cell membrane (Seman 
et al., 2003). A 2005 report from the F. Haag and F. Koch-Nolte (Bannas et al., 2005) 
laboratories discussed the possibility that the GPI anchor mediates segregation of ART2.2 to 
the lipid raft microdomains of the plasma membrane and that this segregation regulates 
activity and specificity of ART2.2. This report used mouse ART2.2 stably-transfected 
mouse lymphoma cells (DC27.10) and demonstrated that two known substrates of ART2 
(P2X7 and LFA-1) are partially localized to the lipid raft microdomain and are acted upon by 
the GPI-anchored ART2.2 (Bannas et al., 2005). Art2 expression in the mouse is restricted 
to spleen, lung, liver and skeletal muscle (Glowacki et al., 2002). The Art2 gene in humans 
and chimpanzees contains three premature stop codons (Haag et al., 1994). 
Arta and Art4 were cloned from human testis and spleen, respectively (Levy et al., 
1996; Koch-Nolte et al., 1997). Arta is expressed in human skeletal and cardiac muscle 
(Levy et al., 1996) and also mouse cardiac muscle, skeletal muscle, liver, and testis 
(Glowacki et al., 2002). Art4 expression is restricted to human spleen, ovary and intestine 
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(Koch-Nolte et al., 1997) and also mouse cardiac muscle, spleen, testis and in various days of 
embryonic development (E11 and E17) (Glowacki et al., 2002). Both enzymes are predicted 
to be GPI-anchored, similar to ART 1. ARTS and ART4 enzymatic activities have not been 
characterized. It is known that they both lack the R-S-EXE motif that has been found in 
many known, active arginine-specific ARTs (Glowacki, et al., 2002). Three regions 
characterize the R-S-EXE motif: region 1 contains the arginine located on abeta-strand, 
region 2 consisting of an aromatic residue-X-serine-X-serine, and region 3 which contains 
the active site glutamate on abeta-strand (Domenighini &Rappuoli, 1996). Another motif, 
different than the R-S-EXE motif, identified in many bacterial toxin mono-ADP-
ribosyltransferases and also a few vertebrate mono-ADP-ribosyltransferases, is made up by a 
histidine-containing region, an aromatic hydrophobic amino acid-rich segment and the 
active-site glutamate region (Domenighini &Rappuoli, 1996; Okazaki &Moss, 1999). 
Human ART3 closely matches the latter motif description, while mouse ART3 does not align 
with any of the described motifs. Human ART4 aligns well with the first two regions in the 
R-S-EXE motif description, but the active site glutamate region contains KKE, not the 
correct EXE sequence. Mouse ART4 does not align well with any of the described motifs. It 
may be that these family members have an entirely different target specificity or that they 
have lost enzyme activity all together (Glowacki, et al., 2002). Recent chromosomal 
localization and characterization of candidate genes identified Art4 as the gene for the 
Dombrock blood group antigens (Parusel et al., 2005). These antigens were discovered 30 
years ago based on their reactivity with antibodies induced by blood transfusions (Swanson 
et al., 1965). Anew panel of monoclonal antibodies specific for human ART4 was produced 
in the laboratories of F. Haag and F. Koch-Nolte (Parusel et al., 2005), and this same group 
has recently developed antibodies specific for each of the human and mouse ARTs 1-4 
(Koch-Nolte et al., 2005). 
Arts was originally cloned from murine lymphoma cells (Okazaki et al., 1996) and is 
expressed in adult mouse skeletal and cardiac muscle, testis, and lung tissue (Glowacki et al., 
2002). The amino- and carboxyl-terminal signal peptides found in the sequence of ART1 
and other ARTs that are characteristic of the GPI-anchor signal are not present in ART5, 
although an amino-terminal hydrophobic signal sequence is found. Rat mammary 
adenocarcinoma (MVIU) cells transformed with the cDNA of Arts exhibited membrane 
associated, but apparently not GPI-anchored, transferase and NAD glycohydrolase activities 
(Okazaki et al., 1996). ART5 has been shown to have significant NAD glycohydrolase 
activity but upon auto-ADP-ribosylation the enzyme was found to have higher transferase 
activity (Weng et al., 1999). 
Much of the mammalian ADP-ribosylarginine hydrolase (ADPRH) activity has been 
localized to the cytoplasm (Chang et al., 1986; Moss et al., 1988), and while some transferase 
activity has also been localized there (Kharadia et al., 1992), the majority of the ARTs appear 
to be GPI-anchored. ADPRH removes the ADP-ribose moiety from ADP-ribosylated 
proteins, completing the ADP-ribosylation cycle shown in Figure 1. ARTS is the only 
known ART that does not contain the GPI anchor signal, so this ART may be involved in an 
intracellular ADP-ribosylation cycle. Database searches recently revealed that both the 
human and mouse genome contain three Adprh genes (Adprh 1-3) (Glowacki et al., 2002). 
Recent investigations into the genomic organization and promoter analysis of mouse Adprh 1 
gene revealed that this gene has many characteristics of a housekeeping gene (Aoki et al., 
2005). It was found that the 5' -flanking sequence lacked TATA and CCAAT motifs and 
contained many GC boxes, all of which are indicative of a housekeeping gene. This study 
also found an Sp 1 a element in the Adprh 1 gene and that this element is essential for full 
Adprh 1 promoter activity (Aoki et al., 2005). ADPRH activity has been identified in 
cultured chicken skeletal muscle cells, rat and rabbit skeletal muscle, rat heart, liver, kidney, 
and brain (Kim &Graves, 1990). The 39-kDa ADPRH enzyme was first cloned from rat 
brain and Northern analysis showed hydrolase mRNA in rat brain, lung, liver, kidney, spleen, 
testis, heart and skeletal muscle (Moss et al., 1992) and the enzyme appears to be localized to 
the cytoplasm (Chang et al., 1986; Moss et al., 1988). The mammalian ADP-ribosylation 
cycle has not been corroborated to the degree that the Rhodospirillum rubrum cycle, 
described earlier, has. 
The addition of [32P]NAD+ to intact cells or cell lysates has shown that several 
proteins can be labeled with mono-[32P]ADP-ribose (Kharadia, et al., 1992; Huang et al., 
1996). The finding that the GPI-anchor of ART2 can confer substrate specificity and control 
activity of ART2 (Bannas et al., 2005) is very important in establishing the endogenous 
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substrates of the ARTs. A brief list of the proteins that have been identified that can be 
ADP-ribosylated include: membrane proteins such as integrins, Cat+ ATPase, p40 (a tyrosine 
kinase regulator), as well as intracellular proteins that include G3PDH, the heat shock protein 
BiP, desmin, neuronal phosphoprotein B-50/GAP-43, Ga, rho, and actin (Koch-Nolte & 
Haag, 1997, and references therein). Table 1 lists some of the eukaryotic enzymes and 
substrates. 
Klebl et al. (1997) identified target proteins of mono-ADP-ribosylation in T-tubules 
of rabbit skeletal muscle. Using radioactive NAD+ to label proteins they found 18 proteins 
that were modified and suggested that the 42-kDa protein to be the stimulatory G protein, 
Gsa. They found that ADP-ribosylation of Gsa inhibited T-tubular adenylate cyclase activity, 
and this activity could be rescued by using novobiocin, a specific inhibitor of mono-ADP-
ribosylation (Klebl et a1.,1997). 
Using Chinese-hamster ovary cells, Di Girolamo's group found that ADP-
ribosylation of the G protein ~3 subunit prevented inhibition of type 1 adenylate cyclase (Lupi 
et al., 2000). This same group then went on to show that the ADP-ribosylated ~3y 
heterodimer was unable to activate phosphoinositide 3-kinase and phospholipase C-~32. They 
suggest that this modification might be a general mechanism for termination of ~~ 
heterodimer signaling. In this same study they found that ADP-ribosylation of the ~~ 
heterodimer was increased by hormonal activation of G-protein-coupled receptors (Lupi et 
al., 2002). 
Integrin a7 has also been identified as a maj or cell surface substrate for an arginine-
specific ART in C2C 12 mouse myoblast cell cultures (Zolkiewska &Moss, 1993). Integrins 
are a family of proteins that form heterodimers consisting of an a and ~3 subunit. The 
combinations of the a and a ~3 subunit are responsible for allowing the integrins to 
preferentially bind to specific components of the extracellular matrix (ECM), where they 
participate in regulation of cell shape, migration, growth and differentiation. The a7~31 
heterodimer is an exclusive laminin receptor involved in cell adhesion and interactions 
between myoblasts and the ECM. The biological significance of the ADP-ribosylation of 
integrin a7 has not been determined, as ADP-ribosylated a7 is able to bind to X31 and form a 
functional heterodimer (Zolkiewska &Moss, 1995). Recent work in Zolkiewska's (Zhao et 
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al., 2005) laboratory has shown that at low NAD+ concentrations (10 µM) the a7 subunit is 
mono-ADP-ribosylated and at higher levels (100 µM) it is bi-ADP-ribosylated. The mono-
ADP-ribosylated a7 subunit, dimerized to the X31 subunit, was shown to have an increased 
binding to laminin in vitro. Intracellular levels of NAD+ are in the range of 200 to 1000 µM, 
while the concentration of extracellular NAD+ is in the sub-micromolar range (Ohlrogge et 
al., 2002). Local levels of extracellular NAD+ could be dramatically increased upon lysis of 
the cells due to inflammation or fusion of myoblasts to become multinucleated myotubes. 
A recent article from Zahradka's (Yau et al., 2003) group using amono-ADP-
ribosylation specific inhibitor, meta-iodobenzylguanidine (MIBG), revealed that proliferation 
and migration of porcine coronary artery smooth muscle cells were suppressed by MIBG. 
They also reported that the mitogen stimulated increase in c-fos and c-myc gene expression 
could be blocked by incubation with MIBG, and this was found to be due to inhibition of 
phosphorylation of protein kinase N and PRK2. These two proteins have been shown to be 
critical intermediates linking Rho-dependent activation of c-fos to serum response factor 
(SRF) (Yau et al., 2003). Another article from this group (Yau et al., 2004) examined the 
effect MIBG had on the differentiation of rat L6 skeletal myoblast cells in culture. They 
suggest that mono-ADP-ribosylation is required at a stage prior to myoblast fusion but after 
myogenic determination. In this work they found that MIBG blocked the expression of 
myogenin and p21 using Western blot assays. They also found that MIBG had minimal 
effects on [32P]NAD+ labeling of cell surface proteins, indicating an intracellular ART was 
being inhibited by the MIBG. This finding agrees with the work of Kharadia et al. (1992) in 
which ADP-ribosylated MIBG was found in homogenates of 12-day chick embryo myogenic 
cells. 
Desmin, the muscle-specific intermediate filament (IF) protein, has been identified as 
an in vitro substrate for arginine-specific mono-ADP-ribosylation (Huang et al., 1993, 1996). 
Intermediate filaments form a stable intracytoplasmic filamentous network connecting 
myofibrils to each other and to the plasma membrane skeleton, and are localized to the Z-
disk of mature myofibrils. Desmin has been used as an early marker for myogenesis and is 
one of the first muscle-specific proteins to be expressed in embryonic development (Li et al., 
1997). ADP-ribosylation of desmin has been studied extensively here at Iowa State 
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University in Dr. Graves' and Dr. Huiatt's laboratories. The effect of mono-ADP-
ribosylation on desmin assembly was examined (Yuan et al., 1999) and it was reported that 
the phosphate group is very important for the inhibition of desmin filament formation by 
ADP-ribosylation. It was proposed that the negative charges of the phosphates are important 
in masking the positive charge of the modified arginine residue. It is interesting to note that 
the main arginine reside that is ADP-ribosylated (Arg48 of the head domain) (Zhou et al., 
1996) is very near to a protein kinase A phosphorylation site found at serine 50 (Geisler & 
Weber, 1988; Inagaki et al., 1988). Phosphorylation of this serine also inhibits desmin 
intermediate filament assembly. ADP-ribosylated desmin is unable to assemble into 
intermediate filaments, and assembled desmin intermediate filaments have been shown to 
disassemble upon incubation with recombinant ART enzyme and NAD+. 
ADP-ribosyltransferase activity has been detected in many mammalian tissues and 
the presence of a regulatory ADP-ribosylation cycle has been proposed (Williamson &Moss, 
1990) (Figure 1). This brief review of data from the current literature demonstrates that 
ADP-ribosylation in both prokaryotes and eukaryotes is emerging as an important regulatory 
process. The identification of specific functions, substrates, cellular localization sites and 
expression of the transferases in skeletal muscle will provide valuable information about the 
specific pathways that ADP-ribosylation may regulate. 
Vertebrate skeletal muscle myogenesis 
The basic outline of skeletal myogenesis is well characterized and descriptions can be 
found in a number of recent references (Sabourin & Rudnicki, 2000; Berkes & Tapscott, 
2005; Blais et al., 2005). The skeletal muscle of vertebrates is derived from the embryonic 
myotome. The origin of the myotome is the mesoderm. Initially the paraxial mesoderm 
accumulates to form 2 thickened streaks. This paraxial mesoderm begins to sequentially 
segment into somites, which are blocks or segments of cells that differentiate into the 
sclerotome and dermamyotome and eventually the dermatome and myotome. The myotome 
is formed from cells that delaminate from the dermamyotome lips and migrate underneath 
the dermamyotome, lying between it and the sclerotome. The myotome continues to 
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differentiate into distinct entities that give rise to progenitor cells that form specific groups of 
anatomical muscles (Pownall et al., 2002; Hollway &Currie 2005). The dorsal area of the 
myotome forms the epaxial myotome and the ventral portion of the myotome forms the 
hypaxial myotome. The epaxial myotome will give rise to the epaxial deep back muscles, 
while the hypaxial myotome will form the bulk of the ventral body wall muscles and limb 
muscle progenitors. 
The understanding of the complex program of myogenesis has been aided greatly by 
the use of myogenic tissue culture models such as the cell lines L6, C3H/lOTl/2, and C2C12 
(Yaffe, 1968; Reznikoff et al., 1973; Yaffe & Saxel, 1977a,b; Blau et al., 1985). The 
discovery of MyoD (Davis et al., 1987) as a gene that was a key regulator of myogenesis was 
very important. This finding helped lead the way in discovering the conserved family of 
myogenic regulatory factors (MRFs), MyoD, Myf5, Myogenin, and MRF4. These factors 
are all basic helix-loop-helix (bHLH) DNA regulatory proteins (Pownall et al., 2002). The 
MRFs have the ability to induce conversion of many nonmuscle cell types into muscle. The 
products of several important genes have been identified to have a regulatory role over the 
expression of the MRFs. These genes include paired-type homeobox genes (Pax3 and Pax7), 
homeobox genes (Six 1, Prrx 1, Msx 1), members of the Wnt superfamily, Noggin, and Dach2 
(Pownall et al., 2002; Kardon et al., 2002). 
Gene targeting studies have identified a hierarchical relationship between the MRF 
genes (Pownall et al., 2002; Berkes &Tapscott, 2005). MyoD and Myf5 are thought of as 
required for commitment to the myogenic lineage and there seems to be compensation 
mechanisms that allow MyoD and Myf5 to be functionally redundant. Myogenin and MRF4 
have classically been described as transcription factors that are intimately involved in 
expression of the terminal muscle phenotype. Recent investigations into MRF4 expression in 
the Myf5:MyoD double-null mouse reveals that with uncompromised MRF4 expression 
skeletal muscle can still be formed (Kassar-Duchossoy et al., 2004). This seems to point to 
MRF4 as also being involved in muscle cell determination. Understanding the role that 
MRF4 plays in myogenesis has been complicated by the fact that Myf5 and MRF4 are 
located in tandem and expression of each gene is not completely independent of the other 
(Berkes &Tapscott, 2005). 
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Terminal differentiation is the process by which mononucleated precursor cells 
withdraw from the cell cycle, begin to express muscle specific proteins, and fuse to form 
multinucleated myotubes (Lassar et al., 1994; Skapek et al., 1995). Myotubes continue to 
mature with increased expression of muscle specific proteins and the formation of myofibrils 
and also the migration of their nuclei to the periphery of the myotube. MRF4 has been 
shown to play a role in terminal differentiation of myoblasts (Pownall et al., 2002), along 
with the recently identified role of a myogenic determination gene (Kassar-Duchossoy et al., 
2004). Given the complex network of temporal and spatial expression of the MRF genes it is 
likely there is a slight degree of genetic redundancy built into the program of myogenesis. 
The interaction of the MRF proteins with various other protein and protein complexes 
such as the bHLH E proteins and the inhibitor bHLH proteins (Id, Twist, MyoR, Mist-1), the 
Mef2 family of transcription factors, histone acetyltransferases and deacetylases (Sartorelli et 
al., 2005; Berkes & Tapscott, 2005; Lluis et al., 2006) all have important roles in the 
transcriptional regulation of myogenesis. Another important transcription factor involved in 
regulating myogenesis is c-Myc. This transcription factor is known to be a strong inhibitor 
of terminal differentiation (Denis et al., 1987; Xiao et al., 2003) and exerts this effect in 
complex with Max and Mad family proteins or by interacting with various c-Myc binding 
proteins (Xiao et al., 2003). The expression of c-Myc decreases upon the induced 
differentiation of C2C 12 myoblasts to elongated multinucleated myotubes (Yeilding et al., 
1998; Tomczak et al., 2004). As reported, c-Myc can act as a negative regulator of the 
integrin a7 promoter (Xiao et al., 2003) in C2C 12 cell cultures, and that upon differentiation 
of these cultures c-Myc level decrease while integrin a7 levels increase dramatically. 
Cell cycle regulators play a very important role in the process of terminal 
differentiation. The cyclins are a family of proteins that bind to and activate cyclin-
dependent kinases, which regulate cell cycle progression through phosphorylation of various 
other proteins. There are also families of proteins that are inhibitors of the cyclin-dependent 
kinases. Cyclin-dependent kinase inhibitor lA (P21) is involved in terminal differentiation 
in a variety of cell culture models (Halevy et al., 1995; de Alvaro et al., 2005) and is very 
important in permitting cessation of the cell cycle that is required for the terminal 
differentiation of myoblasts. 
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Known inhibitors of mono-ADP-ribosylation have been shown to modify the activity 
of a variety of cells, including neurons, activated cytotoxic T cells, macrophages, and muscle 
cells (Koch-Nolte &Haag, 1997). ADP-ribosylation was found to play a role in myogenesis 
through the use of 3-aminobenzamide, aspecific inhibitor of ADP-ribosylation (Farzaneh et 
al., 1982). Primary cultures of embryonic chick myoblast cells were treated with 3-
aminobenzamide and it was found that cell fusion and creatine kinase activity were 
reversibly inhibited with the treatment. However, 3-aminobenzamide, at the levels used in 
the above study, inhibits both poly- and mono-ADP-ribosylation (Duncan et al., 1988). 
Additional work in Shall's laboratory led the authors to suggest that the inhibition of poly-
ADP-ribosylation caused the observed results (Farzaneh et al., 1988). Research at Iowa State 
University using an arginine-specific mono-ADP-ribosyltransferase inhibitor, MIBG, was 
initiated to examine the possibility that inhibition of mono-ADP-ribosylation might also be 
involved in myoblast differentiation (Kharadia et al., 1992). This study showed that MIBG, 
at 15-60 µM concentrations, could reversibly inhibit both proliferation and differentiation of 
primary cultures of embryonic chick myoblast cells. 
Recent investigations using MIBG in muscle cell culture models have been aimed at 
identifying the cellular processes affected by inhibition of mono-ADP-ribosylation. 
Investigations in Peter Zahradka's laboratory using both primary cultures of porcine coronary 
artery smooth muscle cells (SMC) (Yau et al., 2003) and rat L6 skeletal myoblast cells (Yau 
et al., 2004) have shown that mono-ADP-ribosylation is required for proper proliferation 
(SMC) and differentiation (L6 myoblasts). In the study using SMC it was observed that upon 
stimulation of the cells with various growth factors mono-ADP-ribosylation was activated, 
and that this activity could be specifically inhibited by MIBG treatment. The SMC also did 
not show normal proliferation or migration upon treatment with MIBG. This study was also 
the first of its kind to identify a link between MIBG and c-fos gene expression, which implies 
mono-ADP-ribosylation regulates induction of the c-fos gene (Yau et al., 2003). The c-fos 
protein, FOS, is a maj or component of the activator protein-1 (AP-1) transcription factor 
complex, which includes members of the JUN family (Glover &Harrison, 1995). Multiple 
pathways can lead to mitogen stimulated c-fos gene and this report examined the MAP 
kinase, PI3-kinase, and Rho-dependent activation of c-fos through serum response factor 
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(SRF) pathways. They found that phosphorylation of PRK1/2, a critical intermediate step 
linking Rho to SRF, was inhibited by treatment with MIBG. It is interesting to note that 
bacterial toxin mediated mono-ADP-ribosylation of Rho and other GTP-binding proteins has 
been published (Moss &Vaughan, 1988; Yau et al., 2003; Aktories 1994). SRF regulates a 
number of muscle and growth factor-inducible genes. SRF is not specific to muscle and its 
association with a variety of co-regulatory proteins (including the myocardin-related 
transcription factors) is believed to be important in its regulation of skeletal muscle gene 
expression (Li et al., 2005). 
Expression of myogenin and cyclin-dependent kinase inhibitor lA (P21) are inhibited 
upon treatment of rat L6 skeletal myoblasts with MIBG (Yau et al., 2004). As described 
earlier the role of myogenin has been established as a key regulator of terminal 
differentiation using various genetic knockouts in the mouse model (Pownall et al., 2002). 
The role of P21 in muscle differentiation is not that of a transcription factor, but rather as an 
important regulator of cell cycle progression. P21 is a member of the cyclin-dependent 
kinase inhibitors and its expression leads to withdrawal from the cell cycle. This cessation of 
proliferation is critical in leading to the terminally differentiated state. This study (Yau et al., 
2004) also examined the effect of various inhibitors of ADP-ribosylation on the protein 
levels of many proteins involved in the myogenic program. The dual mono- and poly-ADP-
ribosylation inhibitor 3-aminobenzamide as well as the poly-ADP-ribosylation inhibitor 
PD128763 had no effect on the protein levels of P21, myogenin or myosin heavy chain 
(MHC). Protein levels of MyoD and MHC were not examined with the above two inhibitors, 
but these levels were not affected by treatment with MIBG. This study also examined the 
effect of MIBG on the ADP-ribosylation of cell surface proteins and found that MIBG had 
no effect on this ADP-ribosylation. This result is in agreement with previous work that 
showed an intracellular ART is sensitive to MIBG inhibition (Kharadia et al., 1992). These 
reports suggest that mono-ADP-ribosylation is a critical event in the stages of terminal 
differentiation. 
The previous brief review of data from the current literature demonstrates that the 
post-translational modification by mono-ADP-ribosylation in myogenesis is an important 
regulator in cell cycle control and in terminal differentiation. The identification of specific 
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functions, substrates, cellular localization sites and expression of the transferases in skeletal 
muscle will provide valuable information about the specific pathways that ADP-ribosylation 
may regulate. 
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Enzyme/Source Substrate Effect References 
Ectoenzymes: 
ART1 
Human,rat,mouse Integrin,defensin/Arg 
Inhibits substrate 
activity 
(Zolkiewska et 
a1.,1992) 
ART2(.1/.2)Rat,mouse P2X7 
NAD-induced T 
cell death 
(Seman et al., 
2003) 
ART3 
Human,rat,mouse Unknown Unknown 
(Koch-Nolte et 
a1.,1997) 
ART4 
Human,rat,mouse Unknown Unknown 
(Koch-Nolte et 
a1.,1997) 
ARTS Human Unknown/Arg Unknown 
(Koch-Nolte et 
a1.,1997) 
ART6(A,B)Chicken p33/actin/Arg28-206 
Inhibits substrate 
activity 
(Tsuchiya et 
a1.,1994) 
ART7 Chicken Unknown 
Inhibits substrate 
activity 
(Davis and 
Sha11,1995) 
Intracellular: 
Arg-specific 
Hamster,human G(beta)/Arg129 
Inhibits substrate 
activity (Lupi et a1.,2000) 
Cys-specific Human GDH/Cys 
Inhibits substrate 
activity 
(Herrero-Yraola et 
a1.,2001) 
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CHAPTER 2. EXPRESSION OF ADP-RIBOSYLATION ENZYMES IN MOUSE 
EMBRYOS AND MUSCLE CELL CULTURES 
A paper to be submitted to Cell and Tissue Research 
Benjamin D. Brooks, Mary Sue Mayes, James M. Reecy, Ted W. Huiatt 
Abstract 
Skeletal muscle myogenesis is a highly regulated process involving distinct changes 
in activation of transcription factors and gene expression driven by these transcription 
factors. Various regulatory signals from the local cellular environment play an important 
role in the commitment of cells to the myogenic pathway that eventually leads to terminal 
differentiation into multinucleated myotubes to form skeletal muscle. ADP-ribosylation 
activity has been detected in many avian and mammalian adult cardiac and skeletal muscle 
samples, but it is currently not known which enzymes are responsible for this activity, or if 
these same enzymes are expressed in the developing somites during embryogenesis. ADP-
ribosylation has also been shown to be required for terminal differentiation in skeletal muscle 
cell cultures; however its mechanism of action has not been determined. This investigation 
examined the expression of the key ADP-ribosylation enzymes during embryo development 
in the mouse and during terminal differentiation in mouse C2C 12 skeletal myoblast cell 
cultures. We also examined the effect of meta-Iodobenzylguanidine (MIBG), a known 
specific inhibitor of ADP-ribosyltransferase enzyme activity, on gene expression of select 
myogenic regulatory factors known to control terminal differentiation. The results 
demonstrated that Art 1, Arta, Arts and Adprh are expressed in the developing mouse 
embryos and that Arts expression displayed the most restricted localization, mainly in the 
dorsal-medial lip of the dermamyotome, of the ADP-ribosylation enzymes. The localization 
of Arts correlates with the known localization of integrin oc7, a known substrate for ADP-
ribosylation. Our investigations using C2C 12 cell cultures as a model for terminal 
differentiation confirmed that MIBG inhibits differentiation of these cells. Inhibition with 
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MIBG correlated with the failure to express Myodl, P21, and myogenin at distinct time 
points during the terminal differentiation process as compared to control treated cells. The 
expression of Artl, Arts and Adprh were also shown to possess temporal patterns that were 
significantly affected by treatment with MIBG. Our results demonstrate the expression of 
key ADP-ribosylation enzymes during both somite development in the embryo and during 
terminal differentiation of C2C 12 cell cultures. These data show that ADP-ribosylation may 
play an important role in determination and differentiation of skeletal muscle cells and that 
specific myogenic factors are regulated during differentiation by ADP-ribosylation. 
Introduction 
The spatial and temporal expression of genes in the embryo often provides the first 
clues as to what biological processes the genes are involved in. The mRNAs for Artl, Arta, 
Arts and Adprh are expressed in adult skeletal and cardiac muscle in the mouse. In the 
mouse myogenic cell line C2C 12 Arta expression is not detected. It is not known which of 
the enzymes, if any, are expressed in myoblast or myoblast precursor cells. It is also not 
known if expression of any of the Arts is colocalized with expression of the hydrolase. Cell 
culture studies using C2C 12 cells can only provide information about terminal 
differentiation. By using developing mouse embryos we aim to investigate mono-ADP-
ribosyltransferase expression in the early steps of myogenesis. To determine if any of these 
genes are expressed in the somite during early myogenesis we performed comparisons of 
Artl, Arta, Arts, and Adprh gene expression with that of Myodl gene expression using in 
situ hybridization on developing mouse embryos. 
The activity of mono-ADP-ribosyltransferase increases upon differentiation 
(Kharadia et al., 1992; Huang et al., 1996; Yau et al. 2004) of muscle cell cultures and this 
activity can be inhibited by treatment with meta-Iodobenzylguanidine (MIBG), (Kharadia et 
al., 1992; Yau et al. 2004). The inhibitor studies have shown that mono-ADP-ribosylation is 
essential for terminal differentiation, but it is not known which of the three mono-ADP-
ribosyltransferases expressed in muscle is responsible, or if MIBG treatment has any effect 
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on the expression of the Arts or Adprh. To determine gene expression levels of Artl, Arts, 
Adprh and key genes involved in terminal differentiation (Myodl, myogenin and P21) during 
differentiation of the mouse myoblast C2C 12 line, with and without MIBG treatment, we 
performed quantitative reverse transcriptase PCR on total RNA isolates. 
The above experiments allowed us to examine the expression of the Arts during early stages 
of myogenesis in developing mouse embryos as well as during the important stages of 
terminal differentiation in C2C 12 cells. 
Materials and Methods 
Cloning of cDNAs and DIG-probe production 
Artl and Adprh cDNA were obtained by PCR performed on adult mouse skeletal 
muscle cDNA (OriGene Technologies, Rockville, NID). The resulting PCR products were 
cloned into pBluescript-SK+ using the Bam HI and Xho I sites. Plasmids with cDNAs of 
Arta, Arts and Myodl were obtained from American Type Culture Collection (Manassas, 
VA). The vector for Arta was pBluescript-SK+, and the vector for Myodl and Arts was 
pT7T3D-Pac. All cDNA encoding plasmids were sequenced at The DNA Facility of the 
Iowa State University Office of Biotechnology using the facility's Applied Biosystems Inc. 
ABI 3730 DNA Analyzer. Gene accession numbers and DIG-probe alignments are presented 
in Table 1. 
All plasmids were linearized with Not I or with Xho I, depending on which RNA 
transcription start site was being used. Linearized plasmids were gel purified and ethanol 
precipitated and then used as templates for anti-sense and sense digoxigenin (DIG)-UTP 
labeled riboprobe synthesis. The transcription mixture contained 1µg linearized template 
cDNA, transcription optimized SX buffer (Promega, Madison, WI), DTT (lOmM final 
cone), recombinant RNasin ribonuclease inhibitor (1 unit/µl final cone), DIG RNA Labeling 
Mix (10 X) (Roche, Indianapolis, IN), T3 or T7 RNA polymerase (Promega, Madison, WI) 
(2 units/µl final cone) and water to a final volume of 20 µl. Transcription was performed for 
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2 hours at 37°C. Riboprobes were then subjected to alkaline hydrolysis by addition of an 
equal volume of 80 mM NaCHCO3, 120 mM Na2CO3, pH 10.2 to the transcription reaction 
and incubation at 60°C for 35-50 minutes. Riboprobes were then purified by precipitation 
with 0.15 volumes of 4M LiCI and 2.5 volumes of 100% ethanol and resuspended in DEPC-
treated water. Labeling efficiency was determined by a spot test, according to instructions in 
the DIG RNA Labeling Mix (10X) (Roche, Indianapolis, IN). Absorbance readings at 230, 
260, 280, and 325 nm were observed to determine concentration of the riboprobes. 
Embryo Processing 
Embryos from C57BL/6J mice were obtained from timed-pregnant females. 
Embryos were harvested in cold PBS with all extra-embryonic membranes and amnion 
removed. Embryos were fixed overnight at 4°C in 4% (w/v) paraformaldehyde in PBS, 
washed once with 0.1% Tween 20 (w/v) in PBS (PBT) and then stored in 90°Io methanol at 
-20°C until use. 
In Situ Hybridization 
Procedures for whole-mount in situ hybridizations were done by modification of the 
methods of Wilkinson (1993). Embryos were rehydrated in a graded series of methanol, 
followed by two washes in PBT. Samples were then treated with 6% hydrogen peroxide in 
PBT for 7 minutes at room temperature (RT), then washed 3 times by 5 minutes at RT. All 
samples were then digested with 10 mg/ml proteinase K for 10 minutes at RT. Samples are 
post fixed with 0.2% glutaraldehyde, 4% paraformaldehyde in PBT for 20 minutes at RT. 
After washes in PBT samples were prehybridized for 3 hours at 65° in prehybridization 
solution (50% deionized formamide, SX SSC pH 4.5, 2% blocking reagent, 0.1%Tween 20, 
0.5% CHAPS, 50 µg/ml yeast RNA, 5 mM EDTA, 50 µg heparin). This solution was then 
removed and prehybridization solution containing 10-300 ng/ml of riboprobe was added to 
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the embryos and allowed to hybridize at 65°C overnight. The riboprobe solution was then 
removed followed by 5 washes with prehybridization solution at 65°C. Successive additions 
of 2X SSC (pH 7.1) were done 3 times, with 5 minutes at 65°C between additions. This 
mixture was then removed and 2 washes of 0.1% CHAPS, 2X SSC were performed with 
incubation for 30 minutes at 65°C. Samples were then digested with 20 µg/ml RNase A in 
0.1% CHAPS, 2X SSC for 1 hour at 37°C. After this samples were washed 4 times with 
malefic acid buffer, twice with PBS, and once with PBT. Samples then are placed into 
blocking solution for 2-3 hours at RT. This solution is replaced with about 2 ml of alkaline 
phosphatase-conjugated Fab fragments of anti-DIG antibodies (Roche, Indianapolis, IN) and 
incubated overnight at 4°C. Embryos were then washed 4 times with 0.1%Bovine serum 
albumin (BSA) in PBT, 3 times in NTMT buffer and then probes were immunologically 
detected with NBT/BCIP as the chromogenic substrate according to manufacturer's 
instructions (Roche). 
Microscopy and Digital Imaging 
Embryos were photographed with an Olympus SZH-10 stereomicroscope (Leeds 
Precision Instruments, Minneapolis, MN) using a Zeiss Axiocam HRC digital camera and 
Axiovision Software (Carl Zeiss Inc., Thornwood, NY). Digital images were captured and 
plates assembled using Freehand 9.0 (Adobe Systems Incorporated). 
Cell culture 
C2C 12 cells were obtained from American Type Culture Collection (Manassas, VA). 
C2C 12 cells were maintained in Dulbecco's Modification of Eagle's Medium (OMEN), 1X 
with 4.5 g/L, L-glutamine, &sodium pyruvate (Mediatech, Inc., Herndon, VA) supplemented 
with 10% fetal bovine serum (Invitrogen, Carlsbad, CA) and 1 % antibiotic-antimycotic 
solution (Mediatech, Inc., Herndon, VA). Differentiation was induced by replacing the 10% 
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fetal bovine serum with 2% horse serum (Invitrogen, Carlsbad, CA). All cells were cultured 
at 37°C in a 5% CO2-humidified chamber. m-Iodobenzylguanidine hemisulfate salt 
(MIBG)(Sigma, St. Louis, MO) was added to media at a final concentration of 50 µM for all 
MIBG treated cells. 
RNA extraction/reverse transcription 
Total RNA was extracted from the C2C 12 cultured cells and mouse embryos of 
stages E10.5-E12.5 using TRIzoI reagent (Invitrogen, Carlsbad, CA) according to 
manufacturer's instructions. Embryos were homogenized in TRIzoI regent using a small 
glass mortar and pestle. Reverse transcription (RT) for synthesizing the first-strand cDNAs 
from the total RNA was carried out using random hexameric primers (Promega, Madison, 
WI) and M-MLV reverse transcriptase (Promega, Madison, WI) with the inclusion of RNasin 
Ribonuclease Inhibitor (Promega, Madison, WI) according to the manufacturer's 
instructions. All total RNA used for reverse transcription reactions was treated with RQ1 
RNase-Free DNase (Promega, Madison, WI) following the manufacturer's instructions 
before being used in the reverse transcription reaction. 
RT-PCR 
Mouse embryonic first-strand cDNA was amplified using an Eppendorf Mastercycler 
gradient machine (Eppendorf, Hamburg, Germany). 10 µl Eppendorf MasterMix (2.5X), 1 
µl reverse transcription reaction, primer mix (contains both primers, final concentration of 
most concentrated primer was 600 nM, other primer was relative in concentration as per 
Table 2), and molecular biology grade water (RPI Corp., Mt. Prospect, IL) was used in a 25 
µl total volume PCR reaction. Reaction products were size fractionated by agarose gel 
electrophoresis (1 % agarose in 1 X TAE buffer, with 0.5 µg ethidium bromide/ml) and 
visualized by UV light. A secondary PCR reaction was performed using 1-5 µl of the 
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primary reaction with the same conditions above as no products were visualized after the 
primary amplification. Primers and expected product sizes are listed in Table 2. Cycle 
settings for both primary and secondary reactions were as follows: 94°C for 60 seconds (1 
cycle), 94°C for 30 seconds -- 55°C for 40 seconds -- 72°C for 40 seconds (25 cycles), 72°C 
for 120 seconds (1 cycle). 
Quantitative RT-PCR 
Levels of first-strand cDNA from C2C 12 cultured cells were quantitated by real-time 
PCR using the Brilliant SYBR Green QPCR master mix (Stratagene, La Jolla, CA) on 
Stratagene's Mx4000 multiplex quantitative PCR system according to the manufacturer's 
instructions. Reaction efficiencies for each primer pair (gene) were calculated using 3 to 5 
fold dilutions (5 dilutions total) of adult mouse skeletal muscle cDNA (OriGene 
Technologies, Rockville, MD). The Mx4000 Software Package (Stratagene, La Jolla, CA) 
was used to view and analyze all standard curves and to determine all QRT-PCR efficiencies. 
Efficiencies were used in a mathematical equation to determine the relative quantification of 
a target gene in comparison to a normalizer gene using the equation of Pfaffl (2001). 
Samples were calibrated to reflect expression levels relative to the Day 0 samples. 
Expression was normalized to Polr2a gene expression. Primers, final primer concentrations 
and expected product sizes are listed in Table 2. Cycle settings were as follows: 95°C for 10 
minutes (1 cycle), 95°C for 30 seconds -- 55°C for 60 seconds -- 72°C for 60 seconds (40 
cycles), 72°C for 120 seconds (1 cycle). A dissociation curve of 95°C for 60 seconds (1 
cycle), 55°C for 30 seconds (40 cycles, with a 1°C increase in temperature per cycle) was ran 
after each QRT-PCR reaction to establish a melting temperature for all reaction products. To 
determine possible genomic DNA contamination, samples were assayed in the absence of 
reverse transcriptase. Every reaction was done in duplicate, and each duplicate set was ran a 
minimum of 3 times. 
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Statistical Analysis 
The separate-variance t-test with an a level equal to 0.05 was used to compare means 
of relative gene expression across days and treatments. Statistics are listed in Appendix A. 
Results 
Expression of Arts and Adprh in the developing mouse embryo 
To determine if ADP-ribosylation enzymes are expressed in the developing mouse 
embryo we performed reverse transcription PCR on total RNA isolated from E10.5, E11.5 
and E12.5 mouse embryos. The results with primers for Artl, Arta, Arts and Adprh were 
compared with results using primers specific for mouse Myodl, beta-actin (Actb), myogenin 
(Myog), cyclin-dependent kinase inhibitor lA (P21), and polymerise (RNA) II (DNA 
directed) polypeptide A (Polr2a) (Figure 1). RT-PCR results show that Artl, Arta, Arts and 
Adprh are expressed at all stages examined (E10.5 through E12.5). Primer pairs for Actb, 
Polr2a, and Myodl were designed to span an intron/exon junction to ensure no genomic 
DNA contamination of the samples and total RNA isolated from the embryos was treated 
with DNase prior to the reverse transcription reaction. The only products visualized were of 
the correct size (see Table 2 for predicted sizes) indicating correct amplification and no 
contamination with genomic DNA. 
To determine the spatial and temporal expression patterns of Artl, Arta, Arts, and 
Adprh in mouse embryos we performed in situ hybridization with digoxigenin-labeled 
riboprobes (Figures 2, 3, 4). The results revealed that Arts (Figure 2) is the most restricted in 
expression pattern to the somites, while the others (Artl, Arta, Adprh (Figure 3)) showed a 
broader pattern of expression in the developing mouse embryo. Expression of Myodl was 
determined at the same developmental stages (Figure 4) to provide a known marker for 
skeletal muscle differentiation. 
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As shown in figure 2a, in E10.5 embryos Arts expression is restricted mainly to 
somites with increased expression in the dorsal-medial (DML) lip of the dermamyotome. 
Arts expression is not present in the posterior most somites (Figure 2a) at E10.5. Arts 
expression at E10.5 (Figure 2a) is present throughout both the epaxial and hypaxial myotome 
areas, similar to Myodl expression at E10.5 (Figure 4a). Art5 expression at El 1.5 (Figure 
2b) shows a lower level of expression in the somites and appears in more posterior somites 
than had been observed at E10.5 (Figure 2a). Art5 expression is present in all of the 
posterior somites, with little to no expression of Arts at El 1.5 seen in somites anterior to the 
forelimb bud. Thus, expression was decreased in the more developed, anterior somites, and 
increased in the less developed, posterior somites, suggesting that expression of Arts in 
somites is limited to a brief time period. Expression of Arts in E12.5 embryos (Figure 2c) is 
similar to the pattern observed in the somites at E11.5. Arts expression at E12.5 does appear 
to be more widespread throughout the entire embryos, compared with E11.5, with a noted 
increase in the forelimb buds seen at E12.5. In parallel, we produced sense probes for each 
of the genes examined to determine specificity of the anti-sense probes. In situ hybridization 
with a sense probe for Arts (Figure 2d) showed no labeling. No labeling was seen with any 
of the other sense probes (data not shown). 
Artl expression (Figure 3a) and Adprh expression (Figure 3b) show localization in 
many tissues, including distinct expression in somites at E10.5. Artl expression does not 
appear in the anterior most somites, with no expression seen anterior to the forelimb bud seen 
at E10.5 (Figure 3a). Adprh expression (Figure 3b) is present in the anterior somites at 
E10.5, with expression also observed in the both limb buds. Expression of these genes did 
not show any changes with the stages of development (data not shown) that were examined 
in this study (E10.5, E11.5, E12.5). 
Arta expression at E10.5 (Figure 3c) is widespread with increased expression 
observed in the olfactory pit. Somite staining is also pronounced at this stage with 
expression seen in all somites, including the posterior somites, similar to Myodl (Figure 4a). 
Arta at E12.5 (Figure 3d) shows ubiquitous expression in the whole embryo. 
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Myodl expression (Figure 4) is restricted to the somites and limb bud areas at the 
sites of epaxial, hypaxial and limb muscle differentiation. Limb bud expression of Myodl 
increases with development. 
Quantitative Reverse Transcription PCR on differentiating C2C12 cell cultures 
Template amplification was quantified by determining the threshold cycle (CT) based 
on the fluorescence detected within the geometric region of the semilog plot. Theoretically, 
in the exponential phase of the PCR reaction one cycle is equivalent to the doubling of the 
PCR target template (Rutledge &Cote, 2003). Standard curves using set dilutions were 
made for each primer pair to determine the actual PCR efficiency. Relative concentration 
between the forward and reverse primers had a dramatic effect upon PCR efficiency and the 
optimal relative concentrations were determined for each primer pair and are listed in Table 
2. Reaction efficiencies were calculated using the software from the Mx4000 (Stratagene) 
thermocycler. The corresponding real-time PCR efficiency (E) of one cycle in the 
exponential phase is calculated according to the equation: E=10~-lisl°peg (Rasmussen, 2001). 
Efficiencies were used in a mathematical equation to determine the relative quantification of 
a target gene in comparison to a normalizer gene, Polr2a, using the equation of Pfaffl (2001). 
Samples were calibrated to reflect expression levels relative to the Day 0 samples. Primer 
pairs for Actb, Polr2a, and Myodl were designed to span an intron/exon junction to ensure 
no genomic DNA contamination of the samples. Dissociation curves were also carried out 
after all reactions to ensure that only a single melting temperature peak was observed. 
Relative gene expression levels in different C2C 12 cell cultures are shown in Figures 
5, 6, and 7. Expression levels were normalized using Polr2a gene expression to account for 
reverse transcription efficiency differences and cDNA sample loading variation. All cells 
were induced to differentiate with low serum exposure beginning at day 0. Day 0 samples 
were collected before addition of the low serum differentiation media and all expression 
levels were calibrated to be relative to day 0. Art 1 expression in control cells showed a trend 
toward an increase of expression with days in differentiation media, with a significant 
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(p=0.017) increase from day 3 to day 4 (Figure 5). Art 5 expression in control cells followed 
a similar pattern to Artl expression, and a significant (p=0.031) increase in Arts expression 
from day 3 to day 4 was also observed (Figure 5). Observation of cultures by light 
microscopy showed that at day 0 cells were near 75-80°Io confluent, at day 3 cells were 
fusing to from myotubes and at day 4 the majority of cells were multinucleated myotubes. 
Cells treated with MIBG did not fuse, as reported earlier (Kharadia et al., 1992). Artl 
expression in MIBG treated cells was relatively level for the entire time course examined and 
was significantly (p<0.017) lower than control cells at all times measured (Figure 5). The 
significant increase of Artl seen in control cells from day 3 to day 4 was not seen in treated 
cells. Arts expression in MIBG treated cells showed a small increase with days in 
differentiation media up to day 3, with a decrease at day 4. This is in sharp contrast to the 
significant increase of Arts expression from day 3 to day 4 seen in control cells (Figure 5). 
Arts expression in control cells was significantly (p<0.022) higher than in MIBG treated 
cells at all time points. 
Adprh expression in control cells did not increase between day 1 and day 2 samples, 
but a significant (p=0.0017) increase was seen at day 3 (Figure 6). Day 4 Adprh expression 
was similar to levels seen in day 1 and day 2. MIBG treated cells had a significantly 
(p<0.01) higher expression level of Adprh at day 1 and day 2, compared to controls, but 
treated cells after days 3 and 4 showed a lower level of Adprh expression as compared to 
respective controls, resulting in an overall decrease in expression after 4 days of MIBG 
treatment. Levels of expression of P21 in control cells were level for day 1 and day 2, with a 
significant (p=0.009) increase at day 3 and a return to near day 1 levels at day 4 (Figure 6). 
Expression of P21 in MIBG treated cells was higher in day 1 and day 2 samples compared to 
control samples and shows a slight decrease in expression from day 3 to day 4. MIBG 
treatment eliminated the significant transient increase in expression of P21 at day 3 seen in 
the control cells. Myodl expression in control cells was low and steady in days 1 and 2, but 
a significant (p<0.009) increase occurred at day 3, and a return to previous levels was 
observed at day 4 (Figure 7). Treated cells actually displayed a decrease in Myodl 
expression over the time course (Figure 7), and the significant peak at day 3, as observed in 
control cells, was not seen. Myogenin expression in control cells was low in day 1 and day 2 
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samples with an increase above these levels seen in day 3 and day 4 samples. Myogenin 
expression in MIBG treated cells remained at very low basal levels over the entire course of 
MIBG treatment (Figure 7) and did not peak at day 3 as the control cells did. 
Overall the expression of Artl and Arts increased with terminal differentiation in 
control cells. Expression levels of Artl and Arts increased significantly (p<0.032) with 
fusion of myoblasts to form multinucleated myotubes (day 3 compared to day 4 expression 
levels). MIBG treated cells saw a significant (p<0.031) decrease in expression of Artl and 
Arts from day3 to day 4. Expression levels in control cells of Adprh, Myodl, Myog, and 
P21 peaked at day 3 and all levels were significantly (p<0.015) higher than their respective 
levels at day 2 and day 4. These results are in contrast to those for expression levels of Myog 
and Myodl in MIBG treated cells in which a decrease was seen from day 2 to day 3. 
Expression of Adprh and P21 in treated cells did increase from day 2 to day 3 but not to the 
extent seen in control cells. 
Discussion 
In this study we identified expression of Artl, Arta, Arts, and Adprh in the 
developing mouse embryo of stages E 10.5, E 11.5 and E 12.5 using both RT-PCR and in situ 
hybridization with digoxigenin-labeled riboprobes. This is the first study to demonstrate that 
Artl, Arta, Arts, and Adprh are expressed in developing mouse embryos. Expression of Arts 
and Adprh in developing mouse embryos implicates the presence of an endogenous ADP-
ribosylation cycle. Glowacki et al., (2002) reported that, in adult mouse tissues, expression is 
tightly restricted. Art 1 expression is most prominent in skeletal muscle, cardiac muscle, lung 
and liver. Arta expression is found in cardiac muscle, skeletal muscle, testis and liver. Arts 
expression is restricted to testis, skeletal muscle, cardiac muscle, and lung tissue (Okazaki & 
Moss, 1999; Glowacki et al., 2002). Adprh expression has not been characterized as well, 
however recent research (Aoki et al., 2005) showed that the 5' -flanking sequence has 
characteristics of a housekeeping gene and involvement of Sp transcription factors are 
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consistent with previous reports (Moss et al., 1992) of widespread Adprh expression in 
mammalian tissues. 
We demonstrated herein, by RT-PCR on embryonic total RNA, that Artl, Arta, Arts 
and Adprh are expressed at all embryonic stages examined (E10.5 through E12.5). This is in 
contrast with earlier work (Glowacki et al., 2002) showing little to no Art (1-5) expression in 
embryonic samples using RT-PCR. This contrast could be due to the fact that two tandem 
amplification reactions of 25 cycles were used in our study whereas one reaction of 31 cycles 
was used in the Glowacki study. Tandem amplifications were used, in which a small aliquot 
of the primary reaction was amplified in the second reaction, because no amplification 
products for any of the genes could be visualized after size fractionation by agarose gel 
electrophoresis and ethidium bromide staining of the primary reaction. The only products 
visualized were of the correct size (Figure 1) indicating successful amplification with the use 
of the secondary reaction. 
It is interesting to note that the expression of Arts was restricted to more anterior 
somites than Myodl expression was at E10.5. Expression of Arts at E11.5 was seen in all 
somites posterior to the forelimb bud, suggesting that Arts expression correlates with a 
distinct timing in the developmental stage of the somites. This may indicate an important 
role in the temporal expression pattern of Arts during myogenesis. 
The expression pattern of Arts may correlate with the expression of a potential 
substrate of mono-ADP-ribosyltransferase, integrin a7. Previous research (Zolkiewska & 
Moss, 1993; 1995) has shown that integrin a7 is ADP-ribosylated in various skeletal muscle 
cell models (mouse C2C12 and G8 cultures and also harvested rabbit skeletal muscle). ART 
activity is known to increase upon differentiation of myoblasts into myotubes (Kharadia et 
al., 1992) and integrin a7 (Itga7) expression has also been shown to increase during 
differentiation (Xiao et al., 2003; Tomczak et al., 2004). Results described herein showed 
that Arts expression is restricted to somites in E10.5 through E12.5 and previous research 
(yelling et al., 1996; Bajanca et al., 2004) has demonstrated that integrin a7 first appears in 
the somites at E10.5 and remains expressed in myogenic cells in later stage embryos and is 
the major integrin receptor on adult skeletal muscle fibers (Song et al., 1993; Ziober et al., 
1993). The localization of Arts and integrin a7 during mouse embryo development and the 
44 
ADP-ribosylation of integrin a7 in myogenic cell cultures suggest a regulatory role for this 
modification in myogenesis. 
Arta expression shows changes in localization with development of the mouse 
embryo. At E10.5 Arta expression is pronounced in the somites and in the olfactory pit, 
whereas at E11.5 (data not shown) and E12.5 expression is ubiquitous. ART3 enzyme 
activity has not currently been described and it is currently not known what role this enzyme 
may play in embryonic development. 
The results of this study confirm that MIBG is an inhibitor of myoblast differentiation 
and that expression of genes critical for terminal differentiation are affected by this treatment. 
Several reports have shown that MIBG, a specific inhibitor of arginine dependent mono-
ADP-ribosylation, can block differentiation of myoblasts into myotubes (Kharadia et al., 
1992; Huang et al., 1996; Yau et al. 2004). This report is the first to examine expression of 
Artl, Arts, and Adprh in response to treatment of mouse C2C12 cells with MIBG. This 
report shows that upon induced differentiation Artl and Arts expression is increased 
significantly. Treatment of cells with MIBG causes a significant decrease in expression of 
Artl and Arts. The significant increase of Artl and Arts seen in control cells at day 4 was 
blocked by the MIBG treatment. It is interesting to note that at day 4 most of the control 
cells had differentiated into multinucleated myotubes. This change in cellular morphology 
occurs simultaneously with significant increases in Artl and Arts expression. Kharadia et al. 
(1992) and Yau et al. (2004) reported that ADP-ribosyltransferase enzyme activity is 
increased upon differentiation of myogenic cell cultures and the increase in this activity is 
inhibited in a competitive manner by treatment with MIBG (Kharadia et al., 1992). This 
report is the first to show that MIBG treatment also decreases gene expression of Artl and 
Arts. 
Adprh expression shows a dynamic variable response to differentiation. Adprh is 
expressed at low levels the first two days of differentiation, with a dramatic increase at day 3 
and a slight decrease at day 4. Interestingly, Adprh expression is increased significantly in 
day 1 and day 2 MIBG treated cells compared to control cells. An increase in expression at 
day 3 is also seen in treated cells, but this increase is not as great as the increase at day 3 in 
control cells. 
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The effect of MIB G treatment on cyclin-dependent kinase inhibitor 1 A (P21) 
expression was also examined in this study. In the absence of MIBG, P21 expression was 
steady for days 1 and 2, with a significant increase seen at day 3 and a slight decrease at day 
4. Interestingly P21 expression was higher in days 1 and 2 treated cells compared to 
controls. The significant increase of P21 expression seen in control cells at day 3 was not 
seen in MIBG treated cells and day 4 expression of P21 in MIBG treated cells decreased to a 
very low level. The role of P21 in muscle differentiation is as an important regulator of cell 
cycle progression. P21 is a member of the cyclin-dependent kinase inhibitors and its 
expression leads to withdrawal from the cell cycle and is critical for establishing the 
terminally differentiated phenotype. 
Previous research (Zolkiewska &Moss, 1993; 1995) has shown that integrin a7 is 
ADP-ribosylated in various skeletal muscle cell culture models (mouse C2C 12 & G8) and 
integrin oc7 (Itga7) expression has also been shown to increase during differentiation (Xiao et 
al., 2003; Tomczak et al., 2004). Integrin a7 promoter is activated by MyoD and myogenin 
in C2C 12 cultures (Ziober &Kramer, 1996) and this study shows that MIBG treatment 
decreases myogenin expression significantly. Our results show myogenin expression is more 
dynamic than Myodl expression in C2C12 cell cultures and this agrees with previous 
research (Tomczak et al., 2004). Myogenin expression in MIBG treated cells was 
significantly lower than in control cells, and the increase in myogenin expression, especially 
at day 3, seen in control cells was not seen in treated cells. 
The block in P21 and myogenin expression seen with MIBG treatment could explain 
why the treated cells failed to differentiate and fuse into multinucleated myotubes. The fact 
that myogenin expression activates expression of integrin oc7 (Ziober &Kramer, 1996), a 
known substrate for amono-ADP-ribosyltransferase in C2C 12 cell cultures (Zolkiewska & 
Moss, 1993; 1995) may be one mechanism by which ADP-ribosylation might influence the 
differentiation process. The only other identified mechanism that might influence the 
differentiation process is the ADP-ribosylation of desmin, an intermediate filament protein. 
This modification may be more relevant in the later stages of differentiation, whereas a block 
in myogenin would affect earlier steps in the process, as seen in this study. Further 
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investigations into the various roles that ADP-ribosylation play in myogenesis are needed to 
define specific mechanisms that are regulated by ADP-ribosylation. 
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Gene ACCESSION 
DIG probe corresponds to 
nucleotides Initial Probe length 
Artl NM 009710 183-948 766 
Arta Y08027 653-1113 461 
Arts U60881 812-1546 735 
Adprh NM_007414 8 85 -1574 690 
Myod 1 NM_010866 1018-1833 816 
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52 
Gene ACCESSION Forward primer (Starting with 5' end) Reverse primer (Starting with 5' end) 
Product size 
(bp) Gene 
QRT-PCR 
Efficiency % 
QRT-PCR Primer 
Conc (nM) 
Art 1 NM 009710 CTT CTG CGT CCC TCA AGA AC CAG CAC CTC CTC CTC TTC AG 125 Art 1 91.05 100F, 200R 
Arta Y08027 GCA TAG CTC TGA CGG CCT AC AAA AGC CTT GAA CGG GAA GT 131 Arta NA Both 600 
Arts U60881 CCT ATC CAG GCG TTG TCT GT AAA GTG GCT GCA GGT CTG AT 144 Arts 78.3 100F, 200R 
Adprh NM_007414 TGC TGA TCC AAG TGA GCA TC AGC ACC TCC ATT AGC CCT TT 148 Adprh 99.9 Both 150 
Myod 1 NM_010866 AGC ACT ACA GTG GCG ACT CA CGG TGT CGT AGC CAT TCT G 114 Myod 1 92.6 450F, 100R 
Myogenin NM_031189 GAA AGT GAA TGA GGC CTT CG AGG CGC TCA ATG TAC TGG AT 104 Myogenin 94.3 100F, 300R 
P21 NM_007669 CTT GTC GCT GTC TTG CAC TC AAT CTG TCA GGC TGG TCT GC 111 P21 96 300F, 100R 
Beta-actin NM_007393 GAT CTG GCA CCA CAC CTT CT GGG GTG TTG AAG GTC TCA AA 138 Beta-actin 95.2 250F, 100R 
Polr2a NM 009089 TGT CTG CTT CTT CTG CTC CA CCA TCT CCT CTC CAC CTT CA 155 Polr2a 101.6 Both 100 
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Figure 5 
Quantitative reverse transcription PCR (QRT-PCR) analysis of Artl and Arts expression 
in differentiating C2C12 cultures. Dark shaded boxes represent cultures treated with 
MIBG; light shaded boxes are control cultures. Relative expression units (REU) (Y-axis) 
were calculated after normalization to Polr2a expression and are relative to expression of 
each gene in day 0 samples. Culture days (X-axis) indicate the number of days the 
cultures had been exposed to differentiation media. Statistics are given in Appendix A. 
Brief overview of Artl statistics: 
In control samples all days are significantly different from each other. 
In treated samples all days are significantly different from each other. 
In same day, different treatment samples all are significantly different from each other. 
Brief overview of Arts statistics: 
In control samples all days are significantly different from each other. 
In treated samples all days are significantly different from each other, except day 2 
treated is not significantly different from day 4 treated. 
In same day, different treatment samples all are significantly different from each other. 
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Figure 6 
Quantitative reverse transcription PCR (QRT-PCR) analysis of Adprh and P21 
expression in differentiating C2C12 cultures. Dark shaded boxes represent cultures 
treated with MIBG. Light shaded boxes are control cultures. Relative expression units 
(REU) (Y-axis) were calculated after normalization to Polr2a expression and are relative 
to expression of each gene in day 0 samples. Culture days (X-axis) indicate the number 
of days the cultures had been exposed to differentiation media. Statistics are given in 
Appendix A. 
Brief overview of Adprh statistics: 
In control samples all days are significantly different from each other, except day 1 
control is not significantly different from day 2 control. 
In treated samples all days are significantly different from each other, except day 1 
treated is not significantly different from day 3 treated. 
In same day, different treatment samples all are significantly different from each other, 
except day 4 control is not significantly different from day 4 treated. 
Brief overview of P21 statistics: 
In control samples all days are significantly different from each other, except day 1 
control is not significantly different from day 2 control, and day 1 control is not 
significantly different from day 4 control. 
In treated samples all days are significantly different from each other, except day 1 
treated is not significantly different from day 3 treated, and day 2 treated is not 
significantly different from day 3 treated. 
In same day, different treatment samples all are significantly different from each other. 
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Figure 7 
Quantitative reverse transcription PCR (QRT-PCR) analysis of Myodl and Myogenin 
expression in differentiating C2C12 cultures. Dark shaded boxes represent cultures 
treated with MIBG. Light shaded boxes are control cultures. Relative expression units 
(REU) (Y-axis) were calculated after normalization to Polr2a expression and are relative 
to expression of each gene in day 0 samples. Culture days (X-axis) indicate the number 
of days the cultures had been exposed to differentiation media. Statistics are given in 
Appendix A. 
Brief overview of Myodl statistics: 
In control samples all days are significantly different from each other, except day 1 
control is not significantly different from day 2 control, and day 2 control is not 
significantly different from day 4 control. 
In treated samples all days are significantly different from each other. 
In same day, different treatment samples all are significantly different from each other. 
Brief overview of Myogenin statistics: 
In control samples all days are significantly different from each other, except day 1 
control is not significantly different from day 2 control. 
In treated samples all days are significantly different from each other, except day 1 
treated is not significantly different from day 3 treated. 
In same day, different treatment samples all are significantly different from each other. 
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CHAPTER 3. GENERAL CONCLUSIONS 
General Discussion 
The major goals of the research presented in this thesis were to: (1) establish the 
pattern of expression of the muscle specific Arts and Adprh during embryonic differentiation, 
using the mouse as an experimental model, and (2) determine the quantitative pattern of 
expression of the Arts and Adprh relative to specific muscle regulatory genes in 
differentiating mouse myoblast cell cultures and the effect of inhibiting ART enzyme activity 
on these expression patterns. Results of this study showed that expression of ADP-
ribosylation enzymes does occur in developing mouse embryos and that Arts gene 
expression is the most restricted, in terms of localization, of the enzymes examined. We also 
show that Arts gene expression localization correlates well with the expression of integrin 
a7, a known substrate of an ADP-ribosyltransferase. This suggests ART5 could play an 
important role in myogenesis. The expression of Artl, Arta and Adprh in the embryos is not 
as restricted to the somites, as Arts was, in developing mouse embryos. These genes may 
play important roles in other tissues that showed expression. 
The studies examining gene expression of ADP-ribosylation enzymes during terminal 
differentiation show, for the first time, that expression of Artl and Arts increase significantly 
with differentiation of C2C 12 cells. Previous work had shown an increase in ART enzyme 
activity upon differentiation of these cells, and this work extends our knowledge of Art gene 
expression during differentiation. In our work with C2C 12 cell cultures we also employed 
the use of a selective inhibitor of the ARTs, meta-iodobenzylguanidine (MIBG), to examine 
gene expression changes that may be affected by this treatment. The expression profiles of 
key genes involved in myogenesis and terminal differentiation (Myodl, myogenin and P21) 
were shown to be significantly affected by the block in ART activity using MIBG. The data 
also suggests that the timely expression, especially at day 3 and day 4, of all of the genes 
examined is critical for proper terminal differentiation. Control cells showed a drastic 
increase of expression of Myodl, myogenin and P21 at day 3, and this peak was not observed 
in MIBG treated cells. 
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The block in P21 and myogenin expression seen with MIBG expression could explain 
why the treated cells failed to differentiate and fuse into multinucleated myotubes. The fact 
that myogenin expression activates expression of integrin a7 (Ziober &Kramer, 1996), a 
known substrate for amono-ADP-ribosyltransferase in C2C 12 cell cultures (Zolkiewska & 
Moss, 1993; 1995) may be one mechanism by which ADP-ribosylation might influence the 
differentiation process. The only other identified mechanism that might influence the 
differentiation process is the ADP-ribosylation of desmin, an intermediate filament protein. 
This modification may be more relevant in the later stages of differentiation, whereas a block 
in myogenin would affect earlier steps in the process as seen in this study. 
The expression of the Arts and Adprh during embryo development and during 
terminal differentiation suggests that ADP-ribosylation plays an important role in these very 
different stages in development. Further investigations into the various roles that ADP-
ribosylation may play in myogenesis are needed to define specific mechanisms that are 
regulated by ADP-ribosylation. 
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APPENDIX A. STATISTICAL DATA 
Day 1 vs Day iM 
t-Test: Two-Sample Assuming Unequal Variances 
Dl Artl DlM Art1 
Mean 1.8566401 0.84938529 
Variance 0.01443109 0.00170594 
Observations 3 3 
Hypothesized 0 
df 3 
t Stat 13.7337208 
P(T<=t) one- 0.00263 
t Critical one- 2.91998558 
P(T<=t) two- 0.00526001 
t Critical two- 4.30265273 
t-Test: Two-Sample Assuming Unequal Variances t-Test: Two-Sample Assuming Unequal Variances 
DI Adprh DIM Adprh DZ Myodl 01 M Myod1 
Mean 1.16386183 3.31918148 Mean 0.64472453 1.08655646 
Variance 0.00418526 0.00088296 Variance 0.02048135 0.02799397 
Observations 3 3 Observations 4 4 
Hypothesized 0 Hypothesized 0 
df 3 df 6 
t Stat -42.815278 t Stat -4.0135322 
P(T<=t) one- 0.00743314 P(T<=t) one- 0.00350509 
t Critical one- 6.31375151 t Critical one- 1.94318027 
P(T<=t) two- 0.01486628 P(T<=t) two- 0.00701018 
t Critical two- 12.7062047 t Critical two- 2.44691185 
t-Test: Two-Sample Assuming Unequal Variances t-Test: Two-Sample Assuming Unequal Variances t-Test: Two-Sample Assuming Unequal Variances 
D1 Myog D1 M Myog DI P21 DIM P21 D1 Art5 D1M Arts 
Mean 1.44015137 0.52522737 Mean 1.66495007 3.22464565 Mean 3.10526208 1.12026127 
Variance 0.09646788 0.02203768 Variance 0.29348246 0.42557433 Variance 0.22364946 0.06047591 
Observations 4 4 Observations 4 4 Observations 4 4 
Hypothesized 0 Hypothesized 0 Hypothesized 0 
df 4 df 6 df 5 
t Stat 5.31551877 t Stat -3.6786481 t Stat 7.44793154 
P(T<=t) one- 0.00301187 P(T<=t) one- 0.00517364 P(T<=t) one- 0.00034409 
t Critical one- 2.13184678 t Critical one- 1.94318027 t Critical one- 2.01504837 
P(T<=t) two- 0.00602373 P(T<=t) two- 0.01034729 P(T<=t) two- 0.00068818 
t Critical two- 2.77644511 t Critical two- 2.44691185 t Critical two- 2.57058183 
Day 2 vs Day 2M 
t-Test: Two-Sample Assuming Unequal Variances t-Test: Two-Sample Assuming Unequal Variances t-Test: Two-Sample Assuming Unequal Variances 
D2 Art1 D2M Artl D2 Adprh D2M Adprh D2 Myodl D2M Myod1 
Mean 4.26438547 1.34542111 Mean 1.08674767 2.40257273 Mean 0.55762394 0.85375268 
Variance 0.23051285 0.05444747 Variance 0.00117781 0.11433805 Variance 0.01610577 0.00721357 
Observations 3 3 Observations 3 3 Observations 3 3 
Hypothesized 0 Hypothesized 0 Hypothesized 0 
df 3 df 3 df 3 
t Stat 9.4710303 t Stat -6.7056052 t Stat -3.3587919 
P(T<=t) one- 0.00124764 P(T<=t) one- 0.01076201 P(T<=t) one- 0.02188624 
t Critical one- 2.35336343 t Critical one- 2.91998558 t Critical one- 2.35336343 
P(T<=t) two- 0.00249527 P(T<=t) two- 0.02152403 P(T<=t) two- 0.04377249 
t Critical two- 3.1824463 t Critical two- 4.30265273 t Critical two- 3.1824463 
t-Test: Two-Sample Assuming Unequal Variances t-Test: Two-Sample Assuming Unequal Variances t-Test: Two-Sample Assuming Unequal Variances 
D2 Myog D2M Myog D2 P21 D2M P21 D2 Art5 D2M Art5 
Mean 1.25841093 0.84781613 Mean 1.40774592 1.99899855 Mean 8.2806884 2.318926 
Variance 0.10890161 0.04635789 Variance 0.04334618 0.03111786 Variance 0.17893679 0.46916085 
Observations 4 4 Observations 3 3 Observations 3 4 
Hypothesized 0 Hypothesized 0 Hypothesized 0 
df 5 df 4 df 5 
t Stat 2.08407988 t Stat -3.7528431 t Stat 14.1731634 
P(T<=t) one- 0.04579297 P(T<=t) one- 0.00994897 P(T<=t) one- 1.5742E-05 
t Critical one- 2.01504837 t Critical one- 2.13184678 t Critical one- 2.01504837 
P(T<=t) two- 0.09158593 P(T<=t) two- 0.01989794 P(T<=t) two- 3.1483E-OS 
t Critical two- 2.57058183 t Critical two- 2.77644511 t Critical two- 2.57058183 
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Day 3 vs Day 3M 
t-Test: Two-Sample Assuming Unequal Variances t-Test: Two-Sample Assuming Unequal Variances t-Test: Two-Sample Assuming Unequal Variances 
D3 Artl D3M Artl D3 Adprh D3M Adprh D3 Myodl D3M Myod1 
Mean 2.63538018 1.01984223 Mean 4.64110477 3.19335426 Mean 2.10052904 0.42616989 
Variance 0.01454292 2.1794E-05 Variance 0.13084921 0.09858013 Variance 0.37069193 0.00380297 
Observations 3 3 Observations 3 3 Observations 4 4 
Hypothesized 0 Hypothesized 0 Hypothesized 0 
df 3 df 4 df 3 
t Stat 18.9313307 t Stat 5.23515896 t Stat 5.47212066 
P(T<=t) one- 0.01679831 P(T<=t) one- 0.00318062 P(T<=t) one- 0.00599899 
t Critical one- 6.31375151 t Critical one- 2.13184678 t Critical one- 2.35336343 
P(T<=t) two- 0.03359662 P(T<=t) two- 0.00636124 P(T<=t) two- 0.01199798 
t Critical two- 12.7062047 t Critical two- 2.77644511 t Critical two- 3.1824463 
t-Test: Two-Sample Assuming Unequal Variances t-Test: Two-Sample Assuming Unequal Variances t-Test: Two-Sample Assuming Unequal Variances 
D3 Myog D3M Myog D3 P21 D3M P21 D3 Art5 D3M Arts 
Mean 4.6237086 0.53357748 Mean 5.87526719 2.36707356 Mean 6.74750703 4.4260065 
Variance 1.15500335 0.02331989 Variance 3.62628244 0.48419178 Variance 0.56474786 1.20441334 
Observations 4 4 Observations 4 4 Observations 4 4 
Hypothesized 0 Hypothesized 0 Hypothesized 0 
df 3 df 4 df 5 
t Stat 7.53589788 t Stat 3.46072895 t Stat 3.49072051 
P(T<=t) one- 0.00242197 P(T<=t) one- 0.01290031 P(T<=t) one- 0.00872849 
t Critical one- 2.35336343 t Critical one- 2.13184678 t Critical one- 2.01504837 
P(T<=t) two- 0.00484393 P(T<=t) two- 0.02580061 P(T<=t) two- 0.01745697 
t Critical two- 3.1824463 t Critical two- 2.77644511 t Critical two- 2.57058183 
Day 4 vs Day 4M 
t-Test: Two-Sample Assuming Unequal Variances t-Test: Two-Sample Assuming Unequal Variances t-Test: Two-Sample Assuming Unequal Variances 
D4 Artl D4M Artl D4 Adprh D4M Adprh D4 Myod1 D4M Myodl 
Mean 9.08881217 0.20263383 Mean 1.78616291 1.1296687 Mean 0.4179107 0.16453999 
Variance 12.0910905 0.00253308 Variance 0.0587065 0.24180631 Variance 0.00355294 0.00213586 
Observations 4 4 Observations 3 3 Observations 3 3 
Hypothesized 0 Hypothesized 0 Hypothesized 0 
df 3 df 3 df 4 
t Stat 5.11054007 t Stat 2.07424494 t Stat 5.81844354 
P(T<=t) one- 0.00724765 P(T<=t) one- 0.06485712 P(T<=t) one- 0.00217205 
t Critical one- 2.35336343 t Critical one- 2.35336343 t Critical one- 2.13184678 
P(T<=t) two- 0.0144953 P(T<=t) two- 0.12971424 P(T<=t) two- 0.00434409 
t Critical two- 3.1824463 t Critical two- 3.1824463 t Critical two- 2.77644511 
t-Test: Two-Sample Assuming Unequal Variances t-Test: Two-Sample Assuming Unequal Variances t-Test: Two-Sample Assuming Unequal Variances 
04 Myog D4M Myog D4 P21 D4M P21 D4 Art5 D4M Arts 
Mean 2.4596891 0.?_3466668 Mean 2.04532515 0.77598092 Mean 23.087163 2.86975793 
Variance 4.0605E-05 0.00313669 Variance 0.06665327 0.02639412 Variance 54.8956963 0.47510489 
Observations 3 3 Observations 4 4 Observations 3 4 
Hypothesized 0 Hypothesized 0 Hypothesized 0 
df 3 df 5 df 3 
t Stat 55.8240002 t Stat 8.32256713 t Stat 4.71098737 
P(T<=t) one- 0.00570142 P(T<=t) one- 0.00020467 P(T<=t) one- 0.02111253 
t Critical one• 6.31375151 t Critical one- 2.01504837 t Critical one- 2.91998558 
P(T<=t) two- 0.01140283 P(T<=t) two- 0.00040934 P(T<=t) two- 0.04222506 
t Critical two- 12.7062047 t Critical two- 2.57058183 t Critical two- 4.30265273 
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Control 
Day 1 vs Day 2, Day 3, &Day 4 
t-Test: Two-Sample Assuming Unequal Variances t-Test: Two-Sample Assuming Unequal Variances t-Test: Two-Sample Assuming Unequal Variances 
Dl Art1 D2 Art1 D1 Artl D3 Art1 DI Art1 D4 Art1 
Mean 1.8566401 4.26438547 Mean 1.8566401 2.63538018 Mean 1.8566401 9.08881217 
Variance 0.01443109 0.23051285 Variance 0.01443109 0.01454292 Variance 0.01443109 12.0910905 
Observations 3 3 Observations 3 3 Observations 3 4 
Hypothesized 0 Hypothesized 0 Hypothesized 0 
df 3 df 3 df 3 
t Stat -8.4263177 t Stat -7.0847784 t Stat -4.1564324 
P(T<=t) one- 0.00689661 P(T<=t) one- 0.0096732 P(T<=t) one- 0.01266043 
t Critical one- 2.91998558 t Critical one- 2.91998558 t Critical one- 2.35336343 
P(T<=t) two- 0.01379323 P(T<=t) two- 0.0193464 P(T<=t) two- 0.02532085 
t Critical two- 4.30265273 t Critical two- 4.30265273 t Critical two- 3.1824463 
t-Test: Two-Sample Assuming Unequal Variances t-Test: Two-Sample Assuming Unequal Variances t-Test: Two-Sample Assuming Unequal Variances 
DI Adprh D2 Adprh DI Adprh D3 Adprh DI Adprh D4 Adprh 
Mean 1.16386183 1.08674767 Mean 1.16386183 4.64110477 Mean 1.16386183 1.78616291 
Variance 0.00418526 0.00117781 Variance 0.00418526 0.13084921 Variance 0.00418526 0.0587065 
Observations 3 3 Observations 3 3 Observations 3 3 
Hypothesized 0 Hypothesized 0 Hypothesized 0 
df 3 df 3 df 3 
t Stat 1.54685798 t Stat -16.264249 t Stat -4.228211 
P(T<=t) one- 0.18267515 P(T<=t) one- 0.00187952 P(T<=t) one- 0.02582042 
t Critical one- 6.31375151 t Critical one- 2.91998558 t Critical one- 2.91998558 
P(T<=t) two- 0.3653503 P(T<=t) two- 0.00375905 P(T<=t) two- 0.05164085 
t Critical two- 12.7062047 t Critical two- 4.30265273 t Critical two- 4.30265273 
t-Test: Two-Sample Assuming Unequal Variances t-Test: Two-Sample Assuming Unequal Variances t-Test: Two-Sample Assuming Unequal Variances 
DI Myod1 D2 Myod1 D1 Myod1 D3 Myod1 D1 Myod1 D4 Myod1 
Mean 0.64472453 0.55762394 Mean 0.64472453 2.10052904 Mean 0.64472453 0.4179107 
Variance 0.02048135 0.01610577 Variance 0.02048135 0.37069193 Variance 0.02048135 0.00355294 
Observations 4 3 Observations 4 4 Observations 4 3 
Hypothesized 0 Hypothesized 0 Hypothesized 0 
df 5 df 3 df 4 
t Stat 0.85046326 t Stat -4.6553085 t Stat 2.85653148 
P(T<=t) one- 0.21694709 P(T<=t) one- 0.00934927 P(T<=t) one- 0.0230453 
t Critical one- 2.01504837 t Critical one- 2.35336343 t Critical one- 2.13184678 
P(T<=t) two- 0.43389419 P(T<=t) two- 0.01869854 P(T<=t) two- 0.04609061 
t Critical two- 2.57058183 t Critical two- 3.1824463 t Critical two- 2.77644511 
t-Test: Two-Sample Assuming Unequal Variances t-Test: Two-Sample Assuming Unequal Variances t-Test: Two-Sample Assuming Unequal Variances 
DI Myog D2 Myog D1 Myog D3 Myog DZ Myog D4 Myog 
Mean 1.44015137 1.25841093 Mean 1.44015137 4.6237086 Mean 1.44015137 2.4596891 
Variance 0.09646788 0.10890161 Variance 0.09646788 1.15500335 Variance 0.09646788 4.0605E-05 
Observations 4 4 Observations 4 4 Observations 4 3 
Hypothesized 0 Hypothesized 0 Hypothesized 0 
df 6 df 3 df 4 
t Stat 0.80207246 t Stat -5.6915718 t Stat -6.5623473 
P(T<=t) one- 0.22654935 P(T<=t) one- 0.00537612 P(T<=t) one- 0.00359831 
t Critical one- 1.94318027 t Critical one- 2.35336343 t Critical one- 2.35336343 
P(T<=t) two- 0.4530987 P(T<=t) two- 0.01075224 P(T<=t) two- 0.00719663 
t Critical two- 2.44691185 t Critical two- 3.1824463 t Critical two- 3.1824463 
t-Test: Two-Sample Assuming Unequal Variances t-Test: Two-Sample Assuming Unequal Variances t-Test: Two-Sample Assuming Unequal Variances 
Dl P21 D2 P21 D1 PZI D3 P21 D1 P21 D4 P21 
Mean 1.66495007 1.40774592 Mean 1.66495007 5.87526719 Mean 1.66495007 2.04532515 
Variance 0.29348246 0.04334618 Variance 0.29348246 3.62628244 Variance 0.29348246 0.06665327 
Observations 4 3 Observations 4 4 Observations 4 4 
Hypothesized 0 Hypothesized 0 Hypothesized 0 
df 4 df 3 df 4 
t Stat 0.86792636 t Stat -4.2531901 t Stat -1.267678 
P(T<=t) one- 0.21720198 P(T<=t) one- 0.0119118 P(T<=t) one- 0.1368416 
t Critical one- 2.13184678 t Critical one- 2.35336343 t Critical one- 2.13184678 
P(T<=t) two- 0.43440396 P(T<=t) two- 0.02382361 P(T<=t) two- 0.2736832 
t Critical two- 2.77644511 t Critical two- 3.1824463 t Critical two- 2.77644511 
t-Test: Two-Sample Assuming Unequal Variances t-Test: Two-Sample Assuming Unequal Variances t-Test: Two-Sample Assuming Unequal Variances 
DI Arts D2 Art5 D1 Art5 D3 Art5 DI Arts D4 Art5 
Mean 3.10526208 8.2806884 Mean 3.10526208 6.74750703 Mean 3.10526208 23.087163 
Variance 0.22364946 0.17893679 Variance 0.22364946 0.56474786 Variance 0.22364946 54.8956963 
Observations 4 3 Observations 4 4 Observations 4 3 
Hypothesized 0 Hypothesized 0 Hypothesized 0 
df 5 df 5 df 3 
t Stat -15.224611 t Stat -8.2040175 t Stat -4.6640778 
P(T<=t) one- 1.1083E-OS P(T<=t) one- 0.00021897 P(T<=t) one- 0.0215122 
t Critical one- 2.01504837 t Critical one- 2.01504837 t Critical one- 2.91998558 
P(T<=t) two- 2.2167E-05 P(T<=t) two- 0.00043793 P(T<=t) two- 0.04302439 
t Critical two- 2.57058183 t Critical two- 2.57058183 t Critical two- 4.30265273 
85 
Control 
Day 2 vs Day 3 &Day 4 
t-Test: Two-Sample Assuming Unequal Variances t-Test: Two-Sample Assuming Unequal Variances 
DZ Art1 D3 Artl D2 Artl D4 Art1 
Mean 4.26438547 2.63538018 Mean 4.26438547 9.08881217 
Variance 0.23051285 0.01454292 Variance 0.23051285 12.0910905 
Observations 3 3 Observations 3 4 
Hypothesized 0 Hypothesized 0 
df 3 df 3 
t Stat 5.61695642 t Stat -2.7402625 
P(T<=t) one- 0.01513202 P(T<=t) one- 0.03566131 
t Critical one- 2.91998558 t Critical one- 2.35336343 
P(T<=t) two- 0.03026404 P(T<=t) two- 0.07132263 
t Critical two- 4.30265273 t Critical two- 3.1824463 
t-Test: Two-Sample Assuming Unequal Variances t-Test: Two-Sample Assuming Unequal Variances 
D2 Adprh D3 Adprh D2 Adprh D4 Adprh 
Mean 1.08674767 4.64110477 Mean 1.08674767 1.78616291 
Variance 0.00117781 0.13084921 Variance 0.00117781 0.0587065 
Observations 3 3 Observations 3 3 
Hypothesized 0 Hypothesized 0 
df 3 df 3 
t Stat -16.942999 t Stat -4.9503877 
P(T<=t) one- 0.00173272 P(T<=t) one- 0.01923333 
t Critical one- 2.91998558 t Critical one- 2.91998558 
P(T<=t) two- 0.00346543 P(T<=t) two- 0.03846667 
t Critical two- 4.30265273 t Critical two- 4.30265273 
t-Test: Two-Sample Assuming Unequal Variances t-Test: Two-Sample Assuming Unequal Variances 
D2 Myod1 D3 Myodl D2 Myod1 D4 Myod1 
Mean 0.55762394 2.10052904 Mean 0.55762394 0.4179107 
Variance 0.01610577 0.37069193 Variance 0.01610577 0.00355294 
Observations 3 4 Observations 3 3 
Hypothesized 0 Hypothesized 0 
df 3 df 3 
t Stat -4.9275845 t Stat 1.72592043 
P(T<=t) one- 0.00800984 P(T<=t) one- 0.09141036 
t Critical one- 2.35336343 t Critical one- 2.35336343 
P(T<=t) two- 0.01601967 P(T<=t) two- 0.18282073 
t Critical two- 3.1824463 t Critical two- 3.1824463 
t-Test: Two-Sample Assuming Unequal Variances t-Test: Two-Sample Assuming Unequal Variances 
D2 Myog D3 Myog D2 Myog D4 Myog 
Mean 1.25841093 4.6237086 Mean 1.25841093 2.4596891 
Variance 0.10890161 1.15500335 Variance 0.10890161 4.0605E-05 
Observations 4 4 Observations 4 3 
Hypothesized 0 Hypothesized 0 
df 4 df 3 
t Stat -5.986821 t Stat -7.277707 
P(T<=t) one- 0.00195697 P(T<=t) one- 0.00267731 
t Critical one- 2.13184678 t Critical one- 2.35336343 
P(T<=t) two- 0.00391395 P(T<=t) two- 0.00535462 
t Critical two- 2.77644511 t Critical two- 3.1824463 
t-Test: Two-Sample Assuming Unequal Variances t-Test: Two-Sample Assuming Unequal Variances 
D2 P21 D3 P21 DZ P~ 1 D4 P21 
Mean 1.40774592 5.87526719 Mean 1.40774592 2.04532515 
Variance 0.04334618 3.62628244 Variance 0.04334618 0.06665327 
Observations 3 4 Observations 3 4 
Hypothesized 0 Hypothesized 0 
df 3 df 5 
t Stat -4.6551347 t Stat -3.6146802 
P(T<=t) one- 0.00935021 P(T<=t) one- 0.00765244 
t Critical one- 2.35336343 t Critical one- 2.01504837 
P(T<=t) two- 0.01870043 P(T<=t) two- 0.01530488 
t Critical two- 3.1824463 t Critical two- 2.57058183 
t-Test: Two-Sample Assuming Unequal Variances t-Test: Two-Sample Assuming Unequal Variances 
D2 ArtS D3 ArtS D2 ArtS D4 Art5 
Mean 8.2806884 6.74750703 Mean 8.2806884 23.087163 
Variance 0.17893679 0.56474786 Variance 0.17893679 54.8956963 
Observations 3 4 Observations 3 3 
Hypothesized 0 Hypothesized 0 
df 5 df 3 
t Stat 3.4211843 t Stat -3.4557036 
P(T<=t) one- 0.00940703 P(T<=t) one- 0.03725077 
t Critical one- 2.01504837 t Critical one- 2.91998558 
P(T<=t) two- 0.01881407 P(T<=t) two- 0.07450154 
t Critical two- 2.57058183 t Critical two- 4.30265273 
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Control 
Day 3 vs Day 4 
t-Test: Two-Sample Assuming Unequal Variances 
Treated 
Day 3M vs Day 4M 
t-Test: Two-Sample Assuming Unequal Variances 
D3 Artl D4 Artl D3M Art1 D4M Artl 
Mean 2.63538018 9.08881217 Mean 1.01984223 0.20263383 
Variance 0.01454292 12.0910905 Variance 2.1794E-05 0.00253308 
Observations 3 4 Observations 3 4 
Hypothesized 0 Hypothesized 0 
df 3 df 3 
t Stat -3.7073728 t Stat 32.1983353 
P(T<=t) one- 0.01705172 P(T<=t) one- 3.2918E-05 
t Critical one- 2.35336343 t Critical one- 2.35336343 
P(T<=t) two- 0.03410344 P(T<=t) two- 6.5836E-05 
t Critical two- 3.1824463 t Critical two- 3.1824463 
t-Test: Two-Sample Assuming Unequal Variances t-Test: Two-Sample Assuming Unequal Variances 
D3 Adprh D4 Adprh D3M Adprh D4M Adprh 
Mean 4.64110477 1.78616291 Mean 3.19335426 1.1296687 
Variance 0.13084921 0.0587065 Variance 0.09858013 0.24180631 
Observations 3 3 Observations 3 3 
Hypothesized 0 Hypothesized 0 
df 3 df 3 
t Stat 11.3576757 t Stat 6.12657886 
P(T<=t) one- 0.00073212 P(T<=t) one- 0.00437145 
t Critical one- 2.35336343 t Critical one- 2.35336343 
P(T<=t) two- 0.00146424 P(T<=t) two- 0.00874291 
t Critical two- 3.1824463 t Critical two- 3.1824463 
t-Test: Two-Sample Assuming Unequal Variances t-Test: Two-Sample Assuming Unequal Variances 
D3 Myod1 D4 Myod1 D3M Myod1 D4M Myodl 
Mean 2.10052904 0.4179107 Mean 0.42616989 0.16453999 
Variance 0.37069193 0.00355294 Variance 0.00380297 0.00213586 
Observations 4 3 Observations 4 3 
Hypothesized 0 Hypothesized 0 
df 3 df 5 
t Stat 5.49226651 t Stat 6.41624753 
P(T<=t) one- 0.00593799 P(T<=t) one- 0.00068234 
t Critical one- 2.35336343 t Critical one- 2.01504837 
P(T<=t) two- 0.01187599 P(T<=t) two- 0.00136467 
t Critical two- 3.1824463 t Critical two- 2.57058183 
t-Test: Two-Sample Assuming Unequal Variances t-Test: Two-Sample Assuming Unequal Variances 
D3 Myog D4 Myog D3M Myog D4M Myog 
Mean 4.6237086 2.4596891 Mean 0.53357748 0.23466668 
Variance 1.15500335 4.0605E-05 Variance 0.02331989 0.00313669 
Observations 4 3 Observations 4 3 
Hypothesized 0 Hypothesized 0 
df 3 df 4 
t Stat 4.02702453 t Stat 3.47516327 
P(T<=t) one- 0.01375938 P(T<=t) one- 0.01273185 
t Critical one- 2.35336343 t Critical one- 2.13184678 
P(T<=t) two- 0.02751877 P(T<=t) two- 0.02546371 
t Critical two- 3.1824463 t Critical two- 2.77644511 
t-Test: Two-Sample Assuming Unequal Variances t-Test: Two-Sample Assuming Unequal Variances 
D3 P21 D4 P21 D3M PZZ D4M P21 
Mean 5.87526719 2.04532515 Mean 2.36707356 0.77598092 
Variance 3.62628244 0.06665327 Variance 0.48419178 0.02639412 
Observations 4 4 Observations 4 4 
Hypothesized 0 Hypothesized 0 
df 3 df 3 
t Stat 3.98599109 t Stat 4.45339332 
P(T<=t) one- 0.01413336 P(T<=t) one- 0.01053564 
t Critical one- 2.35336343 t Critical one- 2.35336343 
P(T<=t) two- 0.02826672 P(T<=t) two- 0.02107127 
t Critical two- 3.1824463 t Critical two- 3.1824463 
t-Test: Two-Sample Assuming Unequal Variances t-Test: Two-Sample Assuming Unequal Variances 
D3 ArtS D4 ArtS D3M Arts D4M Arts 
Mean 6.74750703 23.087163 Mean 4.4260065 2.86975793 
Variance 0.56474786 54.8956963 Variance 1.20441334 0.47510489 
Observations 4 3 Observations 4 4 
Hypothesized 0 Hypothesized 0 
df 3 df 5 
t Stat -3.8050938 t Stat 2.40168807 
P(T<=t) one- 0.03132328 P(T<=t) one- 0.03074617 
t Critical one- 2.91998558 t Critical one- 2.01504837 
P(T<=t) two- 0.06264655 P(T<=t) two- 0.06149234 
t Critical two- 4.30265273 t Critical two- 2.57058183 
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Treated 
Day 1M vs Day 2M, Day 3M, &Day 4M 
t-Test: Two-Sample Assuming Unequal Variances t-Test: Two-Sample Assuming Unequal Variances t-Test: Two-Sample Assuming Unequal Variances 
D1M Artl D2M Art1 D1M Art1 D3M Art1 DIM Art1 D4M Art1 
Mean 0.84938529 1.34542111 Mean 0.84938529 1.01984223 Mean 0.84938529 0.20263383 
Variance 0.00170594 0.05444747 Variance 0.00170594 2.1794E-05 Variance 0.00170594 0.00253308 
Observations 3 3 Observations 3 3 Observations 3 4 
Hypothesized 0 Hypothesized 0 Hypothesized 0 
df 3 df 3 df 5 
t Stat -3.6256478 t Stat -7.0806269 t Stat 18.6552102 
P(T<=t) one- 0.0341819 P(T<=t) one- 0.00968422 P(T<=t) one- 4.0738E-06 
t Critical one- 2.91998558 t Critical one- 2.91998558 t Critical one- 2.01504837 
P(T<=t) two- 0.06836379 P(T<=t) two- 0.01936844 P(T<=t) two- 8.1475E-06 
t Critical two- 4.30265273 t Critical two- 4.30265273 t Critical two- 2.57058183 
t-Test: Two-Sample Assuming Unequal Variances t-Test: Two-Sample Assuming Unequal Variances t-Test: Two-Sample Assuming Unequal Variances 
D1 M Adprh D2M Adprh DIM Adprh D3M Adprh DIM Adprh D4M Adprh 
Mean 3.31918148 2.40257273 Mean 3.31918148 3.19335426 Mean 3.31918148 1.1296687 
Variance 0.00088296 0.11433805 Variance 0.00088296 0.09858013 Variance 0.00088296 0.24180631 
Observations 3 3 Observations 3 3 Observations 3 3 
Hypothesized 0 Hypothesized 0 Hypothesized 0 
df 3 df 3 df 3 
t Stat 4.66818816 t Stat 0.6895131 t Stat 7.69109484 
P(T<=t) one- 0.02147673 P(T<=t) one- 0.28087731 P(T<=t) one- 0.00824419 
t Critical one- 2.91998558 t Critical one- 2.91998558 t Critical one- 2.91998558 
P(T<=t) two- 0.04295347 P(T<=t) two- 0.56175462 P(T<=t) two- 0.01648838 
t Critical two- 4.30265273 t Critical two- 4.30265273 t Critical two- 4.30265273 
t-Test: Two-Sample Assuming Unequal Variances t-Test: Two-Sample Assuming Unequal Variances t-Test: Two-Sample Assuming Unequal Variances 
DIM Myod1 D2M Myodl D1M Myod1 D3M Myodl DIM Myod1 D4M Myod1 
Mean 1.08655646 0.85375268 Mean 1.08655646 0.42616989 Mean 1.08655646 0.16453999 
Variance 0.02799397 0.00721357 Variance 0.02799397 0.00380297 Variance 0.02799397 0.00213586 
Observations 4 3 Observations 4 4 Observations 4 3 
Hypothesized 0 Hypothesized 0 Hypothesized 0 
df 5 df 4 df 4 
t Stat 2.40080259 t Stat 7.40688545 t Stat 10.5002335 
P(T<=t) one- 0.03077984 P(T<=t) one- 0.00088627 P(T<=t) one- 0.00023255 
t Critical one- 2.01504837 t Critical one- 2.13184678 t Critical one- 2.13184678 
P(T<=t) two- 0.06155968 P(T<=t) two- 0.00177253 P(T<=t) two- 0.00046509 
t Critical two- 2.57058183 t Critical two- 2.77644511 t Critical two- 2.77644511 
t-Test: Two-Sample Assuming Unequai Variances t-Test: Two-Sample Assuming Unequal Variances t-Test: Two-Sample Assuming Unequal Variances 
Dl M Myog D2M Myog D1M Myog D3M Myog D1M Myog D4M Myog 
Mean 0.52522737 0.84781613 Mean 0.52522737 0.53357748 Mean 0.52522737 0.23466668 
Variance 0.02203768 0.04635789 Variance 0.02203768 0.02331989 Variance 0.02203768 0.00313669 
Observations 4 4 Observations 4 4 Observations 4 3 
Hypothesized 0 Hypothesized 0 Hypothesized 0 
df 5 df 6 df 4 
t Stat -2.4669779 t Stat -0.0784147 t Stat 3.45373376 
P(T<=t) one- 0.02837015 P(T<=t) one- 0.47002397 P(T<=t) one- 0.01298289 
t Critical one- 2.01504837 t Critical one- 1.94318027 t Critical one- 2.13184678 
P(T<=t) two- 0.0567403 P(T<=t) two- 0.94004793 P(T<=t) two- 0.02596579 
t Critical two- 2.57058183 t Critical two- 2.44691185 t Critical two- 2.77644511 
t-Test: Two-Sample Assuming Unequal Variances t-Test: Two-Sample Assuming Unequal Variances t-Test: Two-Sample Assuming Unequal Variances 
DI M P21 D2M P21 D1 M P21 D3M P21 Dl M P21 D4M P21 
Mean 3.22464565 1.99899855 Mean 3.22464565 2.36707356 Mean 3.22464565 0.77598092 
Variance 0.42557433 0.03111786 Variance 0.42557433 0.48419178 Variance 0.42557433 0.02639412 
Observations 4 3 Observations 4 4 Observations 4 4 
Hypothesized 0 Hypothesized 0 Hypothesized 0 
df 4 df 6 df 3 
t Stat 3.58679756 t Stat 1.79819073 t Stat 7.28459252 
P(T<=t) one- 0.01151375 P(T<=t) one- 0.06112918 P(T<=t) one- 0.00267005 
t Critical one- 2.13184678 t Critical one- 1.94318027 t Critical one- 2.35336343 
P(T<=t) two- 0.02302751 P(T<=t) two- 0.12225837 P(T<=t) two- 0.0053401 
t Critical two- 2.77644511 t Critical two- 2.44691185 t Critical two- 3.1824463 
t-Test: Two-Sample Assuming Unequal Variances t-Test: Two-Sample Assuming Unequal Variances t-Test: Two-Sample Assuming Unequal Variances 
Ol M Arts D2M Arts O1 M Arts D3M Arts D1 M Arts D4M Arts 
Mean 1.12026127 2.318926 Mean 1.12026127 4.4260065 Mean 1.12026127 2.86975793 
Variance 0.06047591 0.46916085 Variance 0.06047591 1.20441334 Variance 0.06047591 0.47510489 
Observations 4 4 Observations 4 4 Observations 4 4 
Hypothesized 0 Hypothesized 0 Hypothesized 0 
df 4 df 3 df 4 
t Stat -3.2941143 t Stat -5.8785894 t Stat -4.7811307 
P(T<=t) one- 0.01504954 P(T<=t) one- 0.00491058 P(T<=t) one- 0.00438414 
t Critical one- 2.13184678 t Critical one- 2.35336343 t Critical one- 2.13184678 
P(T<=t) two- 0.03009907 P(T<=t) two- 0.00982117 P(T<=t) two- 0.00876827 
t Critical two- 2.77644511 t Critical two- 3.1824463 t Critical two- 2.77644511 
88 
Treated 
Day 2M vs Day 3M &Day 4M 
t-Test: Two-Sample Assuming Unequal Variances t-Test: Two-Sample Assuming Unequal Variances 
D2M Artl D3M Artl D2M Artl D4M Artl 
Mean 1.34542111 1.01984223 Mean 1.34542111 0.20263383 
Variance 0.05444747 2.1794E-05 Variance 0.05444747 0.00253308 
Observations 3 3 Observations 3 4 
Hypothesized 0 Hypothesized 0 
df 3 df 2 
t Stat 2.41600414 t Stat 8.33853117 
P(T<=t) one- 0.06849021 P(T<=t) one- 0.00703952 
t Critical one- 2.91998558 t Critical one- 2.91998558 
P(T<=t) two- 0.13698043 P(T<=t) two- 0.01407904 
t Critical two- 4.30265273 t Critical two- 4.30265273 
t-Test: Two-Sample Assuming Unequal Variances t-Test: Two-Sample Assuming Unequal Variances 
D2M Adprh D3M Adprh D2M Adprh D4M Adprh 
Mean 2.40257273 3.19335426 Mean 2.40257273 1.1296687 
Variance 0.11433805 0.09858013 Variance 0.11433805 0.24180631 
Observations 3 3 Observations 3 3 
Hypothesized 0 Hypothesized 0 
df 4 df 4 
t Stat -2.9683204 t Stat 3.69439438 
P(T<=t) one- 0.02060643 P(T<=t) one- 0.01046897 
t Critical one- 2.13184678 t Critical one- 2.13184678 
P(T<=t) two- 0.04121285 P(T<=t) two- 0.02093794 
t Critical two- 2.77644511 t Critical two- 2.77644511 
t-Test: Two-Sample Assuming Unequal Variances t-Test: Two-Sample Assuming Unequal Variances 
D2M Myod1 D3M Myodl DAM Myodl D4M Myod1 
Mean 0.85375268 0.42616989 Mean 0.85375268 0.16453999 
Variance 0.00721357 0.00380297 Variance 0.00721357 0.00213586 
Observations 3 4 Observations 3 3 
Hypothesized 0 Hypothesized 0 
df 4 df 3 
t Stat 7.38170737 t Stat 12.3458588 
P(T<=t) one- 0.00089772 P(T<=t) one- 0.00057242 
t Critical one- 2.13184678 t Critical one- 2.35336343 
P(T<=t) two- 0.00179545 P(T<=t) two- 0.00114484 
t Critical two- 2.77644511 t Critical two- 3.1824463 
t-Test: Two-Sample Assuming Unequal Variances t-Test: Two-Sample Assuming Unequal Variances 
D2M Myog D3M Myog D2M Myog D4M Myog 
Mean 0.84781613 0.53357748 Mean 0.84781613 0.23466668 
Variance 0.04635789 0.02331989 Variance 0.04635789 0.00313669 
Observations 4 4 Observations 4 3 
Hypothesized 0 Hypothesized 0 
df 5 df 4 
t Stat 2.38090722 t Stat 5.34532938 
P(T<=t) one- 0.03154701 P(T<=t) one- 0.00295206 
t Critical one- 2.01504837 t Critical one- 2.13184678 
P(T<=t) two- 0.06309401 P(T<=t) two- 0.00590412 
t Critical two- 2.57058183 t Critical two- 2.77644511 
t-Test: Two-Sample Assuming Unequal Variances t-Test: Two-Sample Assuming Unequal Variances 
D2M PZ1 D3M P21 D2M P21 D4M P21 
Mean 1.99899855 2.36707356 Mean 1.99899855 0.77598092 
Variance 0.03111786 0.48419178 Variance 0.03111786 0.02639412 
Observations 3 4 Observations 3 4 
Hypothesized 0 Hypothesized 0 
df 3 df 4 
t Stat -1.015324 t Stat 9.38808643 
P(T<=t) one- 0.1923571 P(T<=t) one- 0.00035864 
t Critical one- 2.35336343 t Critical one- 2.13184678 
P(T<=t) two- 0.3847142 P(T<=t) two- 0.00071728 
t Critical two- 3.1824463 t Critical two- 2.77644511 
t-Test: Two-Sample Assuming Unequal Variances t-Test: Two-Sample Assuming Unequal Variances 
D2M Arts D3M Arts DZM Arts D4M Arts 
Mean 2.318926 4.4260065 Mean 2.318926 2.86975793 
Variance 0.46916085 1.20441334 Variance 0.46916085 0.47510489 
Observations 4 4 Observations 4 4 
Hypothesized 0 Hypothesized 0 
df 5 df 6 
t Stat -3.2575316 t Stat -1.13371 
P(T<=t) one- 0.01125357 P(T<=t) one- 0.15008669 
t Critical one- 2.01504837 t Critical one- 1.94318027 
P(T<=t) two- 0.02250714 P(T<=t) two- 0.30017338 
t Critical two- 2.57058183 t Critical two- 2.44691185 
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